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ABSTRACT
This dissertation recognizes the enormous potential presented by the everevolving development of liposomes as drug carriers and seeks to offer further
investigation into their useful production and utilization. The first chapter presents the
basic principles governing their formation by self-assembly in water solutions, briefly
describes the most common production methods, and points out essential past advances
that led to their use as drug carriers. Chapter two exemplifies production of liposomes by
the traditional methods of extrusion and sonication, detailing passive and active loading,
as well as physical characterization by Dynamic Light Scattering, microscopy imaging,
and fluorescence spectroscopy. In the next chapter, a novel approach for liposome
preparation that relies on removing a lipid-solubilizing detergent from lipid mixtures by
electrodialysis is introduced and compared to traditional preparation techniques. This
methodology allows accelerated preparation of loaded and purified liposomes,
resembling characteristics of ones prepared by traditional methods, in only a few steps.
The final experimental chapter is focused on achieving controlled release of liposomal
cargo, which is a major roadblock for many current clinical applications. This is realized
by irradiation of liposomes containing PhotoClick lipids, as well as pH sensitive
liposomes activated by internal pH changes resulting from irradiation of organic halogen
solutions. The pairing of X-ray irradiation as a stimulus for releasing chemotherapeutic
loaded cargo from liposomes offers possibility for truly concomitant application of radio
and chemotherapy, potentially resulting in supra-additive efficacy of treating tumors.
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CHAPTER ONE: OVERVIEW OF LIPOSOME DISCOVERY, PRODUCTION, AND
THEIR CAPABILITIES AS DRUG CARRIERS
Based on the two Greek words lipos and soma, meaning “fat” and “body”,
liposomes have unprecedently advanced biomedical and scientific research. Usually
ranging from approximately 20 nanometers to several microns in diameter, liposomes
most notably consist of at least one lipid bilayer resulting from the favorable orientation
and self-assembly of the hydrophobic lipid tails, surrounding a hydrophilic, aqueous core.
The discovery of liposomes can be traced back to the 1960’s, when Alec Bangham and
R.W. Horne observed their formation when creating negatively stained phospholipid
dispersions under electron microscopy at Babraham Institute in Cambridge [1]. In the
decades that followed, research and understanding of liposomes led to their extensive
utilization for fundamental studies and applications in industrial, agricultural, food
production, consumer, and biomedical fields [2-9]. Their biomimetic properties
resembling the phospholipid bilayer membrane of cells [10] also allow for investigations
on the properties of cellular membranes and as a scaffold for reconstitution of membrane
proteins, as well as studies on their biophysical and biological properties such as transport
and interactions [11-13]. Apart from their characteristic spherical bilayer structure,
liposomes are highly customizable with regards to their physical and chemical properties,
making them suitable for a large variety of scientific, medical, and biotechnological
applications.
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Formation, Production, and Characterization of Liposomes
The guiding principle of liposome formation resides in the energetic
unfavourability of exposed hydrophobic components of phospholipids in aqueous
solution. The phospholipid can be defined by two distinct molecular regions; a
hydrophilic head composed of a phosphate and glycerol bridge, which is bound to a
hydrophobic tail composed of fatty acids (Figure 1A) [14]. The simultaneous presence of
the contrasting hydrophobic and hydrophilic regions defines it as an amphiphilic
molecule. A fatty acid and aqueous interface drives grouping of like fatty acid tails to
minimize the free energy of the system by self-assembling into structures such as
micelles, monolayers, bilayers, unilamellar, and multilamellar liposomes (Figure 1B) [1517].
Based on this principle, it was initially understood that upon simple hydration of a
lipid film with an aqueous solution, spontaneous assembly of energetically favorable
liposomes was possible [18]. Although there is still some speculation regarding the exact
mechanism of vesicle formation upon aqueous hydration, it is generally agreed that the
spherical enclosure of the bilayer is one of the most energetically favorable structures
lipid film can attain upon exposure to water molecules, creating a local minima of the
free energy of the system (Figure 2) [15, 16, 19].
It is, however, not enough to hydrate a lipid film with an aqueous solution to
attain a sample of monodisperse and functional liposomes. Self-assembly resulting from
passive exposure of lipid membranes to aqueous solution will result in formation of
various energetically favorable lipid structures as previously mentioned. Liposomes will
also exist in unilamellar and multilamellar form, that is, consisting of a single bilayer or
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multiple concentric bilayers (Figure 1B), of various sizes. Further input of energy is
required, whether it is through physical agitation or chemical environment alteration, to
create a more uniform and functional sample of liposomes [15, 16, 19].

Figure 1.
Typical structure of a phospholipid and phospholipid structures
formed upon hydration. (A) Phosphatidylcholine, a frequently used phospholipid in
liposome preparation. Adapted from van Hoogvest, P. Review – An update on the
use of oral phospholipid excipients [14]. Available under Creative Commons
License. (B) Lipid structures typically formed upon hydration of dehydrated lipid
films. This includes lipid monolayers, lipid bilayers, micelles, unilamellar and
multilamellar liposomes, as well as aggregates of these structures.
Mechanical dispersion and agitation methods utilize externally applied energy to
reform and refine liposomes and lipid structures formed during hydration with an
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aqueous solution. Two such methods which have prominently and dependably been used
for decades includes extrusion and sonication [20-23]. Extrusion involves repeated
refinement of liposomes formed by hydrated lipids by pushing them through pores of a
specific size to create a uniform and monodisperse population of liposomes (Figure 3)
[24, 25]. The understanding of the exact mechanism of liposome formation through
sonication is still evasive, however it involves application of ultrasonic pulsation to a
hydrated lipid solution to create a more uniform population of liposomes. It is likely that
the high frequency vibration, physical agitation, and water cavitation induced by
sonication results in shattering of large lipid structures to reform as small, unilamellar
liposomes [26].

Figure 1.
Free energy diagram of liposome (vesicle) formation. Absolute
relative minima of free energy seen with phospholipid aggregates, as compared to
the local minima seen in formation of multilamellar vesicles (MLV), then large
unilamellar vesicles (LUV), and finally small unilamellar vesicles (SUV). Figure
originally from Lasic 1988 - The Mechanism of Vesicle Formation [16]. Used with
permission from the publisher.
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Figure 2.
Example of an extrusion setup. The metallic block holds an extrusion
assembly, which houses the polycarbonate membrane through which the
polydisperse and multilamellar liposomes are extruded. Extruding action aides in
creating a monodisperse and unilamellar sample of liposomes. Images acquired
from the Avanti Polar Lipids website [https://avantilipids.com/divisions/equipmentproducts].
Beside these two original preparation methods of liposomes, numerous
customizations and modifications have been made to better control their formation. It
would take a whole book to properly describe the basis and exact science pertaining to
each method, however many of the methods beyond some variations of the previously
mentioned mechanical dispersion rely on the removal of organic solvents such as alcohol,
ether, or detergent [27, 28].
Organic solvent removal techniques often require specialized custom devices and
setups to rapidly dilute or remove organic solvents, such as ethanol from lipid/organic
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solvent/loading molecule solutions, to create a sudden shift in the physical and chemical
properties of the environment. This results in decreased lipid solubility, leading lipids to
group their hydrophobic fatty acid tails when exposed to buffer solution, driving the
formation of liposomes and simultaneous entrapment of cargo [29] (Figure 4). In a
similar fashion, ether injection relies on the low boiling point of ether for evaporation
from a lipid solution. Gradual removal of ether as an organic solvent through its
evaporation drives self-assembly of liposomes in the aqueous solution the ether/lipid
solution is initially injected into [30].

Figure 4.
Diagram of basic ethanol injecting setup. A solution of lipids with
ethanol is rapidly diluted by an aqueous buffer to result in liposomes in buffer with
diluted ethanol.
Another well-established method involves the removal of a detergent from a lipid/
detergent mixture [31]. This can be done by utilizing a few different techniques of
detergent removal such as chromatography and dialysis; however, the principal of
liposome formation lies in fusion of assembled lipid structures as the solution loses
detergent to solubilize with. The fusion of these lipid structures creates lipid bilayer disks
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with exposed hydrophobic edges. Further detergent elimination leads to fusion of
adjacent disks, which evolve into spherical liposomes to decrease the span of, and
eventually eliminate hydrophobic edges of the bilayer by curving [15, 16, 32].
It is important to note that the selection of a specific preparation technique cannot
address all difficulties of liposome preparation, nor suit all needs. One method often
surpasses the quality of another but may lack in other aspects. Several factors must be
considered when using a particular method, such as encapsulation efficiency, size and
size distribution of liposomes produced, compatibility with cargo or surface markers of
liposomes, residual traces of solvent, as well as time, effort, and cost needed for
production [2, 3]. This is especially important when creating biomedical products
intended to be used on human patients, as quality and safety become of paramount
importance.
When producing liposomes intended as carriers, it is vital to understand the
properties of the cargo. Passive loading techniques involve formation of liposomes either
entrapping cargo present in the surrounding environment [2, 33] or integrating
hydrophilic or integral membrane components during lipid film drying or liposome
formation. In a self-describing manner, this is a passive process and does not require any
specific driving force or additional energy beyond that which is needed to form the
liposomes.
A more exclusive technique, applicable only to molecules capable of changing
from a membrane permeant to non-permeant state, is described by active loading. The
existence of an electrochemical gradient between the internal and external environments
of the liposomes allows changes in the properties of the loading molecules to modulate
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their ability to permeate through the membrane. One such variation involves liposome
preparation in one external pH environment, with an internal pH capable of adjusting the
ionization of the cargo and its permeability. A buffer exchange, usually performed by
using dialysis, is completed afterwards to generate a significant pH gradient [34]. As an
example, in non-ionized form (neutral), some cargo molecules are membrane permeant
and can diffuse freely through the membrane into the liposome from the external bulk
solution. The diffusion process is often augmented by the established electrochemical
gradients. Upon entering, the different pH drives ionization of the cargo molecule. The
ionized form of the cargo is membrane impermeant, leaving it entrapped within the
liposome. Although this can be a relatively time-consuming process requiring multiple
steps, its desirability resides in its high loading efficiency (Figure 5) [33, 35]. An
alternate approach for active loading utilizes the production of liposomes with a higher
internal vs external concentration of ammonium sulfate to load chemotherapeutic
doxorubicin (DOX). DOX, upon entering the liposome, forms gel-like aggregates due to
loss of solubility when forming a complex with sulfate. As a result, it becomes incapable
of escaping the liposome, leading to DOX concentrations hundred folds higher than those
found outside. The bioavailability of the crystalized, membrane impermeant DOX
molecules is retained [36-38].
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Figure 5.
Principal methods of liposome loading with hydrophilic cargo. Left
side showing passive loading as formation of the liposome leads to encapsulation of
drug molecules at the concentration present in the surrounding buffer. Right side
showing active loading driven by electrochemical gradient (generated by pH
difference in this example) which drives drug entrance into preformed liposome and
ionization of drug molecule, preventing it from exiting the liposome.
Liposomes as Drug Carriers
Beyond furthering membrane studies by exploring protein membrane interactions,
behavior, and characterization, liposomes serve as an excellent platform for carrying
drugs in a protected state within the body [23, 29, 39, 40]. Substances intended for the
treatment of diseases are seldom without unintended off-target effects. Drug molecules
generally stimulate or inhibit behaviors of either foreign or host cells to achieve their
desired effects, yet their activity is often indiscriminate. Systemic applications can be
potentially hazardous and ineffective, as drug molecules are often reactive, unstable, and
frequently target key biological components and processes. These issues are particularly
concerning in instances such as treatment of maladies like fungal infections [41, 42] and
malignant neoplasms [43, 44]. The systemic application of naked drug molecules not
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only limits the amounts and concentrations of drugs that can be safely used to effectively
treat the intended disease but is also often plagued by a short period of bioavailability.
Drug carriers, such as liposomes, attempt to mitigate these issues by retaining and
controlling release of a drug cargo intended for diseased tissue until reaching their
desired target and prolonging their circulation within the body [45, 46]. In this light,
using liposomes as drug carriers resulted in a fruitful and ever-expanding field of
research (Figure 6).

Figure 6.
The versatile use and modification of liposomes as drug carriers.
Apart from drug loading in the core or membrane, liposomes are highly
customizable. Surface modifications are frequently made to better reach and
interact with their intended target (i.e, by using antibodies) as drug carriers or to
avoid the immune system (PEG). Figure originally from Beltran‑Gracia et al., 2019 Nanomedicine review: clinical developments in liposomal applications [45].
Available under Creative Commons License.
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One of the most obvious yet key aspects of liposomes pertaining to their
usefulness as drug carriers is their isolated core. Beyond the ability of holding water
soluble cargo in the core, the intramembranous space of the bilayer also creates a
favorable environment for incorporating small hydrophobic molecules. The loading of
drugs in the liposomes serves many purposes, key among them being the preservation of
the drug cargo from the unstable and chemically active bloodstream environment. On the
other hand, the prevention of premature drug action on non-target tissue, significantly
reducing many side effects often seen from exposed, systemic treatment with the same
drugs [46]. This preservation also acts to increase the overall long-term bioavailability of
the drug and in some instances, increase effective concentrations [47].
In addition to their protective and stabilizing function, liposomes can be produced
of sizes and physical properties that enable self-accumulation in intended regions, such as
tumors, by the enhanced permeability and retention (EPR) effect (Figure 7) [48-50]. This
can be seen by increased accumulation of small liposomes up to 200 nm diameter in
tumor regions due to the porous, leaky capillaries developed among rapidly growing
tumor tissue, as well as their lack of functional lymphatic drainage [51, 52]. Liposomes
that are too small, somewhere around or below 50 nm in diameter, appear to have the
tendency to also collect in the liver through fenestrated endothelium [53]. Contrarily,
larger liposomes are easily detected and captured by the immune cells, resulting in both
liver and spleen accumulation [54]. Furthermore, liposomes can be functionalized to
target specific cells and tissues; for example, folate may be used to target cancer cells
since tumor cells overexpress folate receptors on their surface [55, 56], while
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functionalization with specific antibodies provide endless opportunities to target specific
tissues [57-59].

Figure 3.
The Enhanced Permeability and Retention (EPR) effect presented by
small, PEGylated liposomes. The fenestrated endothelial lining of blood vessels
developed by tumors allow entrance of small liposomes into the tumor tissue. Upon
entrance, liposomes fail to escape because of the ineffective lymphatic drainage in
tumors. Figure originally from Børresen et al., 2017 - Liposome-encapsulated
chemotherapy: Current Evidence for its Use in Companion Animals [50]. Used with
permission from the publisher.
A prominent issue presented by the early attempt to use liposomes as drug carriers
involved a strong immune response from the host upon injection into the bloodstream
[60]. Liposomal membranes can be modified to minimize recognition by the host’s
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immune system mechanisms such as the mononuclear phagocyte system (MPS)/
reticuloendothelial system (RES) [61-63]. Immune response can be evaded by creating a
steric shield over the liposomal surfaces by utilizing polyethylene glycol (PEG) moieties
protruding from the membrane (Figure 6) [64, 65], prolonging their circulation times to
weeks. This revolutionized the study of liposomes as drug carriers as it allowed for their
introduction into a host’s bloodstream without immediate immune response.
An excellent example for liposomes-mediated drug delivery is shown by the
liposomal formulation of doxorubicin. A powerful chemotherapeutic, doxorubicin, most
effectively achieves shrinking tumor tissue at concentrations which are also cardio toxic
[66, 67]. Doxil®, the first FDA approved liposomal drug carrier, uses active loading of
doxorubicin into PEGylated liposomes to avoid immune system detection. Due to their
sub-200 nm diameter, the EPR effect enables self-accumulation at tumor sites, resulting
in a passive and local delivery of high concentration of doxorubicin [36, 68]. Some of the
latest research and innovation pertaining to liposome drug and gene delivery involves the
use of fusogenic liposomes expelling material into cellular cytosol [69, 70]. Finally,
another prominent and potent technique involves producing liposomes that have
membranes capable of changing permeability upon external stimulation, resulting in
controlled or environmentally triggered release of cargo [71].
Triggered Release of Payload from Liposomes
Beyond conventional treatments without the use of drug carriers, liposomes
provide significant advantages and improvements which are already substantial on their
own. It is well understood that beyond reaching a target, the amounts of a drug achieved
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locally must go beyond threshold concentrations to effectively work. More so, it is often
desirable that the high drug concentrations are attained in a short period of time.
PEGylated liposomes consisting of bilayers composed of relatively stable lipid
compositions can take days to effectively release their contents [72]. In this regard,
liposomes that can be triggered to release their cargo retain all the benefits offered by
regular liposomal drug carriers, with the added benefit of being capable of delivering
high concentration of drugs immediately upon application of external stimuli. This is of
key significance especially when dealing with delivery of chemotherapeutics to tumor
sites, where killing cancerous cells with the utmost urgency is often desired to eliminate
their proliferation and potential metastatic behavior.
The need for controlled release is still an unmet challenge. However, efforts are
being taken to better understand how the ability to create and utilize controlled release
liposomes could potentially offer significant improvements in treatment outcomes.
Greater understanding and abilities of synthetic chemistry, as well as nanoparticles,
allows for the creation of lipids and lipid membranes capable of specific chemical or
physical response to stimuli. Such stimuli come in the form of wavelength specific
radiation [73, 74], pH change [75], ultrasound [76], magnetic actuation [77], and
temperature [78]. Furthermore, particles embedded or loaded within liposomes can be
triggered by external near-infrared or X-ray radiation to initiate a cascade of events
leading to the release of the liposome content [79, 80].
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CHAPTER TWO: PREPARATION, LOADING, AND CHARACTERIZATION OF
LIPOSOMES MADE BY SONICATION AND EXTRUSION
Widely recognized as classic preparation methods of liposomes, extrusion and
sonication are reliably and frequently used, decades after their inception [1-4]. In this
respect, this chapter will discuss the production and further physical characterization of
common liposomes by employing microscopy imaging and Dynamic Light Scattering.
Apart from formation, liposomes were also passively or actively loaded with drug
simulating dyes or chemotherapeutic doxorubicin, and successful loading was confirmed
by fluorescence microscopy and spectroscopy. Further analysis of loading was performed
by using fluorescence spectroscopy analysis, which exploited fluorescence selfquenching to monitor dye concentration changes upon liposome membrane solubilization
with non-ionic detergent.
Materials and Methods
Lipids, Loading Molecules, and Buffers
Asolectin (Aso, Sigma-Aldrich), cholesterol (Chol, Sigma-Aldrich), 1,2distearoyl-sn-glycero-3-phosphocholine (DSPC, Avanti Polar Lipids), and 1,2-distearoylsn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG,
Avanti Polar Lipids) (Figure 8) were purchased either in powder or chloroform
solubilized form. The powder lipids were solubilized in chloroform, mixed with the other
lipids at the desired weight ratios in glass vials, then had the solvent removed by placing
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the open vials placed under vacuum for at least 12 hours. Formed lipid films not used
immediately were stored in a freezer at -20 °C. The precursors to all liposome
preparations were the dried lipid films prepared from a mixture of lipids at specified dryweight ratios. The dye molecules used to demonstrate loading included calcein (CAL),
rhodamine 6G (R6G), and acridine orange (AO) (all from ThermoFisher Scientific). An
actual chemotherapeutic loaded into extruded liposomes was doxorubicin (DOX, SigmaAldrich) (Figure 9). The buffers used for all experiments included phosphate-buffered
saline 1x (PBS, Fisher Scientific), 135 mM KCl + 20 mM HEPES prepared from KCl in
dry form (ThermoFisher Scientific) and 1 M HEPES (Sigma-Aldrich), or 150 mM citrate
buffer prepared from sodium citrate dihydrate and citric acid (Fisher Scientific) brought
to pH 4.24 using 1 M HCl.

Figure 8.
Structural details of phospholipids and cholesterol used for
preparation of liposomes. Naturally derived asolectin is a combination of equal
parts lecithin [phosphatidylcholine], cephalin, and phosphatidylinositol, with small
amounts of other phospholipids and polar lipids (“R” indicates possible variable
structure in fatty acid tail). Synthetic lipids 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethyleneglycol)-2000] (DSPE-PEG) and cholesterol were also utilized
for liposome production.
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Figure 9.
Chemical and optical properties of dye and drug molecules passively
and actively loaded into sonication and extrusion prepared liposomes. Fluorescent
dyes calcein (CAL) (ex/em) 495/520 nm, and rhodamine 6G (R6G) (ex/em) 528/550
nm were passively loaded. Fluorescent dye acridine orange (AO) (ex/em) 485/530
nm was both passively and actively loaded. Anthracycline chemotherapeutic
doxorubicin (DOX) (ex/em) 470/560 nm was actively loaded.
Liposome Preparation
Prior to extrusion, the lipid films in the glass vials were slowly hydrated with
appropriate buffer/dye for a minimum of 30 minutes at 45 °C. To complete hydration and
homogenize the mixture, the hydrated samples underwent two freeze/thaw cycles.
Freezing brought the hydrated lipids to -20 °C, and thawing quickly warmed the samples
to 45 °C. Upon final thawing, lipid hydration mixtures were brought to 60 °C right before
placement into the extrusion syringe. The liposomes were extruded at 70 °C with an
Avanti Polar Lipids extruder equipped with specified pore size polycarbonate membrane
filters for a minimum of 61 passes
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Liposome preparation by sonication was completed with a Misonix S-4000 probe
sonicator (Misonix) equipped with a micro-tip. Lipid film hydration was completed in the
same manner as described previously for hydration before extrusion. Immediately prior to
sonication, hydrated mixtures were brought up to 60°C then allowed to cool to room
temperature. Subsequently, the hydrated lipid mixtures were placed into small glass vials
and sonicated on ice for 15 minutes in manual mode at 25% amplitude and a power
transfer of 6-7 W.
Liposome Loading and Dialysis Purification
Passively loaded liposomes were purified of excess dye using dialysis. CAL
loaded liposomes were passively loaded at 3 mM concentration, and R6G liposomes were
loaded at 1 mM dye concentration. Liposome samples were loaded into Float-A-Lyzer
G2 dialysis devices (Spectrum Spectra/Por), Slide-A-Lyzer cassettes (Thermo Fisher
Scientific), or an Ultra-Fast Dialyzer chamber sealed with 100 nm polycarbonate
membranes (Harvard Apparatus). The dialysis devices were placed into pristine buffer
(identical to the hydration buffer) for at least 24 hours. For particularly concentrated dye
in bulk that required thorough liposome purification, dialysis was complete with multiple
rounds of buffer exchange.
For samples being actively loaded, hydration and liposome preparation was
completed in a 150 mM citrate buffer at pH 4.24. Buffer exchange with neutral pH buffer
(PBS 1X or KCl 135 mM + HEPES 20 mM) was completed by overnight dialysis using
the same procedure as for purification of passively loaded liposomes. Active loading for
AO was allowed for a minimum of 24 hours for AO and 48 hours for DOX at 4 °C before
further analysis by microscopy or fluorescence spectroscopy. The external concentration
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of dye/drug active loading was 50 µM for AO and 25 µM for DOX; at these
concentrations, the amount of dye left in the bulk was negligible, and no further
purification was performed.
Liposome Characterization with Microscopy and Dynamic Light Scattering
Imaging was completed with an Olympus IX71 fluorescence microscope
(Olympus Scientific Solutions Americas Corp) equipped with appropriate filter sets. The
emission spectrum of each dye was determined with a FluoroMax4 spectrofluorometer
(Horiba) set in emission mode. The release of encapsulated dyes was observed with the
spectrofluorometer set in kinetics acquisition mode. To verify the load, 100 µL of 5% v/v
Triton X-100 (Sigma-Aldrich) was added to the liposomal solutions in cuvettes.
Size characterization of the liposomes was performed by dynamic light scattering
(DLS) with the Zetasizer Nano ZS (Malvern Instruments) for determination of average
hydrodynamic diameter and size distribution (PDI, polydispersity index) at room
temperature. For each liposome sample we analyzed three sets, and each set consisted of
13 consecutive runs. Each set provided the corresponding average diameter and PDI,
from which the mean values and standard deviations were calculated.
Results and Discussions
Size and Size Distribution: Liposomes Prepared by Hydration, Sonication, and Extrusion
The fate of liposomes in vivo heavily depends on their physical and chemical
attributes. Two such very pertinent and important features are size and size distribution
[5, 6]. Although there does not appear to be a strict numerical cut-off or standard that is
required of liposomes regarding their size or size distribution for biomedical applications,
these factors are key in designating their suitability and safety for such use [6, 7].
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Biodistribution and clearance are greatly influenced by the size of the particles injected
into the bloodstream or subcutaneous tissue of a subject [5, 6, 8-12]. In addition,
liposomes used in such applications must have predictable characteristics, such as a
uniform size distribution, to complete their intended purpose and minimize unintended
side effects from their application [5, 7]. Beyond safety, poor size distributions have been
implicated in impeding pharmacological and pharmacokinetic studies involving
liposomes [6, 13]. In this regard, it is important to assess these two physical properties of
liposomes soon after they are produced. This was done by analyzing the PDI and average
hydrodynamic diameter of samples as analyzed by DLS.
Liposome production is initiated with the hydration of a lipid deposit [13, 14].
Hydration can be utilized only for the preparation of polydisperse and multilamellar
liposomes, therefore further procedures must be taken to improve the quality of
liposomes (i.e., lamellarity, size, and size distribution), such as extrusion and sonication.
The first set of analyses included comparing the average hydrodynamic diameter and PDI
of liposomes prepared by hydration (H), probe sonication (S), and extrusion (E) through
400 nm polycarbonate membranes. The measurements included liposomes composed of
either a regular lipid composition (dry weight ratio of Aso:Chol at 10:4, designated R) or
long circulating PEGylated formulation (dry weight ratio of DSPC:Chol:DSPE-PEG of
8.2:3.8:2.6, designated P) (Table 1). Because the used PEGylated formulation had a
higher lipid phase transition temperature, hydration was completed at 70 °C, rather than
the 45 °C used for regular formulation lipids.
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Table 1.
Physical characterization of liposomes by DLS analysis. Average
hydrodynamic diameter and polydispersity index (PDI) of liposomes composed of
either a regular or PEGylated formulation using hydration, sonication, or extrusion.
*Liposomes were denoted by a two-letter code with the first letter representing
preparation method (hydration = H, sonication = S, extrusion = E) and a second
letter denoting lipid formulation (regular = R, PEGylated = P).
Composition (mg/mL)
Aso:DSPC:Chol:DSPE-PEG
HR 10:0:4:0

Average Diameter,
nm (Mean ± SD)
2352 ± 315

PDI
(Mean ± SD)
1.0

Preparation
Method
Hydration

HP

0:8.2:3.8:2.6

17160 ± 4436

0.333 ± 0.06

Hydration

SR

10:0:4:0

139 ± 1

0.194 ± 0.02

Sonication

SP

0:8.2:3.8:2.6

83 ± 1

0.154 ± 0.02

Sonication

ER

10:0:4:0

267 ± 7

0.162 ± 0

Extrusion

EP

0:8.2:3.8:2.6

317 ± 5

0.015 ± 0.01

Extrusion

As expected, liposomes prepared only by hydration resulted in large and
polydisperse products with inconclusive estimates (Table 1). DLS is well able to analyze
nanoparticles generally ranging in diameter from a few nanometers to several microns.
However, due to the way hydrodynamic radius is calculated based on laser light
scattering in DLS and how sensitive the technique is to aggregates [15, 16], readings
falling outside the range of resolution results in inaccurate and inconclusive data. This is
exemplified by comparison of R and P liposomes prepared by hydration. A Z-average
hydrodynamic diameter calculation is not capable of providing accurate values with
poorly distributed data. This issue is further compounded by the way PDI is calculated
based on the hydrodynamic radius approximation, which is frequently used to assess size
distribution quality. Therefore, the acceptable PDI seen in the hydrated P sample is
essentially nonsensical and is not sufficient for their accurate appraisal.
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To confirm the hydrated sample is indeed very polydisperse and of poor size
quality overall, the formed liposomes were assessed using light microscopy (Figure 10).
In contrast to a very monodisperse (mean PDI < 0.1, Figure 10B) sample of liposomes
prepared by extrusion with the same P lipid composition, the hydrated sample appears to
be a lot more polydisperse and contain more large, non-uniform aggregates (Figure 10A).
This demonstrates that liposomes prepared with only hydration are not suitable for
biomedical and drug delivery application, highlighting the need for further refinement of
hydrated lipids to attain suitable drug carriers.

Figure 10.
Light microscopy images of liposomes. P formulated liposomes
prepared by hydration (A) and extrusion through 400 nm polycarbonate
membranes (B). Edits were made to remove foreign particles in the foreground
from view. Scale bars are 50 µM.
Analysis of size characterization of liposomes prepared by sonication and
extrusion show much more acceptable values of the physical parameters and trends with
both regular and PEGylated formulations for biomedical purposes. Both formulations and
preparation methods result in PDI averages below 0.2, suggesting suitability as drug
carriers [3, 7]. Sonication prepared liposomes appeared to be suitable for decreased
immune detection, as well as capable of exploiting the EPR effect in tumors given their
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average hydrodynamic radius was below 150 nm in both lipid compositions [17-20]. It is,
however, important to note that extrusion prepared liposomes were made using 400 nm
polycarbonate membranes, partially accounting for the significant difference in size
between sonication and extrusion prepared liposomes. Nonetheless, given the greater
versatility of extrusion, it can prepare small unilamellar liposomes resembling the sizes
we achieved with sonication [2, 21] and provides an overall gentler method of liposome
preparation. Although the selection of a polycarbonate membrane pore diameter allows
for partial control of liposome size prepared during extrusion, it does not result in
liposomes exactly reflecting the size of pore diameter [22]. Because of the small sizes of
the prepared samples, imaging with standard light microscopy provides very little
information as even under ideal conditions, the diameter is at or below the limit of
resolution for sonication or extrusion prepared liposomes that serve as drug carriers.
Microscopy serves to confirm the lack of aggregates and absence of large fragments
(Figure 10), which is initially suggested by DLS (Figure 11).

Figure 11.
Size distribution of liposomes prepared by sonication and extrusion.
Graphical size representation on a logarithmic scale of EP liposomes made by
extrusion with a 400 nm polycarbonate membrane (A) and SP liposomes prepared
with 15 minutes of probe sonication.
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Polyethylene glycol (PEG) significantly advances the capabilities and stability of
liposomes by being fused to lipids utilized in membranes for liposome preparation
(Figure 12) [23]. Apart from the immune system evasion capabilities of PEGylated
liposomes [24, 25], the steric properties of PEGylated moieties protruding from
membranes translate into decreased aggregation and a more uniformly sized population
of liposomes [26, 27]. This phenomenon can be observed when comparing regular with
PEGylated formulation liposomes prepared with the same method. For sonication,
average PDI was approximately 20% lower in PEGylated liposomes, and an over 90%
decrease in PDI was observed between PEGylated and regular formulation extrusion
prepared liposomes.
It is, however, improper to assume the differences between regular and PEGylated
lipid composition liposomes can be solely attributed to the presence of PEG on the
surface of the liposomal membrane. The composition of the regular liposomes is
dominated by a mixture of phospholipids, predominantly phosphatidylcholine, cephalin,
and phosphatidylinositol, accompanied by cholesterol. The PEGylated formulation has a
membrane composed only of synthetically made 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)
as membrane components besides cholesterol. This difference results in slight variations
in membrane properties such as fluidity at a given temperature. This is responsible for the
need for preparation at slightly higher temperatures when dealing with R formulation
lipid films in comparison to P formulations.
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Figure 12.
PEGylated liposomes. Liposome with protruding polyethylene glycol
moieties from the phospholipid bilayer membrane. Figure taken from Labruere et
al., Anti–Methicillin-Resistant Staphylococcus aureus Nanoantibiotics [23].
Available under Creative Commons License.
Passive and Active Loading of Liposomes
A key aspect of preparing liposomes as drug carriers includes loading them with a
drug cargo. This can be simulated with a range of dyes that often resemble physical and
chemical properties of drugs encapsulated into liposomes; however, they are cheaper,
offer better visualization capabilities, and are suitable for both passive and active loading
[28, 29]. Both passive and active methods were used for either extrusion or sonication
prepared liposomes.
For the preparation of passively loaded liposomes, dried lipid films were hydrated
with buffer mixed with desired dye concentration (3 mM CAL, or 1 mM R6G). During
formation, some of the molecules are passively entrapped into the aqueous core at
varying efficiencies depending on size, lamellarity, and lipid composition [30, 31]. After
using the designated liposome preparation technique, the liposomes were purified using
dialysis to purge their surrounding solution of unencapsulated cargo. The resulting inner
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dye concentrations were higher than that of their external environment, as confirmed by
the contrast observed under fluorescence microscopy for CAL (Figure 13A) and R6G
(Figure 13B) loaded liposomes.

Figure 13.
Fluorescence microscopy of PEGylated liposomes passively loaded
with drug simulating fluorescent dyes. CAL loaded (A) and R6G loaded (B)
liposomes prepared with extrusion. Scale bar is 30 µM.
Active loading involves creating an electrochemical gradient between the internal
and external environments of the liposomes. To do this, liposomes were initially hydrated
and prepared in an acidic 150 mM citrate buffer of pH 4.24. Afterwards, liposomes
underwent an overnight external buffer exchange with 1X PBS buffer of pH 7.4. AO, a
membrane permeant dye at neutral pH, was introduced to the formed liposomes by
adding it to the neutral, external solution. The electrochemical gradient created by the
difference in external vs internal pH environments drives the unionized, membrane
permeant molecules through the membranes of the liposome [32]. Upon entrance, AO
becomes ionized, making it membrane impermeant. Using this method, one may load
concentrations of dye up to several times above the initial concentration of which it was
introduced [33]. In an identical fashion, liposomes were also loaded with DOX, for which
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the main substitution was the use of 135 mM KCl + 20 mM HEPES solution for buffer
exchange. External starting concentration in the external buffers for actively loaded AO
was 50 µM, and 25 µM for DOX, respectively.
It is important to note that if non-permeant cargo is loaded during liposome
formation, the cargo can effectively be loaded passively, although that does result in
significantly reduced loading efficiency. This is because the driving force of the
electrochemical gradient is not utilized, and drug solubility is limited. Large pH gradients
of a few units between inside and outside the liposome can result in very effective final
loading concentrations (thousands of times higher than final external molecule
concentrations [32, 34]). A common method for active loading of DOX uses an
ammonium sulfate gradient inside prepared liposomes. Upon entering the liposomes,
DOX complexes with sulfate and crystallizes due to the compound’s poor solubility,
resulting in failure to permeate through the liposomal membrane and its prolonged
containment [35, 36].
Cargo Release from Liposomes
Having trace amounts of intended content loaded into liposomes does not qualify
them as useful for many purposes, in particular drug delivery. The success of liposome
preparation often considers the encapsulation efficiency of the cargo into the liposomes
[37, 38]. Although the exact loading efficiency of the sonication and extrusion prepared
liposomes was not assessed, we determined if a significant amount of fluorescent dye was
loaded into our liposomes. This was done by exploiting self-quenching fluorescence
properties of dyes and drugs we used to approximate the loaded concentrations for both
actively and passively loaded liposomes. The phenomenon of self-quenching can be
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observed beyond a threshold fluorescent molecule concentration. Counterintuitively,
beyond a certain concentration, fluorescence signal diminishes with further increase in
concentration (Figure 14). CAL, AO, R6G, and DOX all present self-quenching at bulk
concentrations ranging from 10 µM to 120 µM. Under specific concentrations, the
fluorescence of the dyes increases upon dye addition; however, once the self-quenching
level is achieved, dye addition leads to a significant decrease in fluorescence. Although
the exact mechanism behind this is still somehow unclear, it is understood that the
proximity of the dye molecules interferes with their fluorescent properties, resulting in a
diminished fluorescence emission [39, 40]. Exploiting this unique characteristic, we
attempted to gauge the concentration of fluorescent molecules loaded into the liposomes
after their preparation. Determining whether self-quenching concentrations were
achieved was done by solubilizing the liposomal membrane using a small amount of a
non-ionic detergent, Triton X-100 [41], which releases the cargo into the bulk, leads to its
dilution, and consequently adjusts the fluorescence signal.
Both regular and long circulating liposome formulations and three of the loading
molecules were utilized for this investigation (Figure 15). All samples presented a sharp
increase in fluorescence immediately after detergent addition, indicative of loading
beyond the self-quenching concentration. This suggests that all the liposomes contained
enough cargo to diffuse in the bulk, dilute, and lead to the observed increase in
fluorescence. However, we also observed different evolutions for the different
formulations, which allowed us to better understand the influence of lipid composition on
loading by interpreting the fluorescence spectroscopy data. The extrusion (E) prepared
liposomes of regular (R) formulation, ER, were passively loaded with 3 mM CAL. E
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prepared liposomes of both R and PEGylated (P) formulations were actively loaded with
AO by its addition to buffer exchanged liposomes to concentrations of 50 µM
concentrations. DOX was actively loaded into E prepared P formulation buffer
exchanged liposomes at 25 µM concentration. In every instance, 50 µL of liposomes
were added to 1 mL of buffer and allowed to equilibrate, and liposomes were solubilized
by adding to the cuvettes 100 µL of 5% v/v Triton X-100 (Figure 15).

Figure 4.
Self-Quenching curves of used drug and dyes. Graphs show how
fluorescence increases with concentration up until a peak fluorescence, at which
point increasing molecular concentration results in a diminished fluorescence
concentration for CAL (A), R6G (B), AO (C), and DOX (D).
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Figure 15.
Analysis of dye and drug loading into liposomes. Non-ionic detergent
induced CAL (A) and actively loaded AO (B and C) and DOX (D) release from
regular liposome formulations (red) and PEGylated formulations (blue) induced by
addition of Triton X-100.
Passively loaded ER CAL liposomes showed a rapid increase and sustained,
stable fluorescence resulting from CAL release upon detergent addition (Figure 15A).
Similarly, ER liposomes loaded with AO (Figure 15B) and EP liposomes loaded with
DOX (Figure 15D) showed a sharp increase then plateau in fluorescence, suggesting
large loading concentrations since bulk dilution did not bring the fluorescence signal
under the peak fluorescence intensity (which would be seen as a further gradual decrease
in fluorescence). In contrast, EP liposomes loaded with AO at the identical 50 µM
concentration used in ER liposomes showed a sharp increase, followed by a decay in
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fluorescence, suggesting loading concentrations of cargo high enough to exhibit selfquenching behavior, yet low enough to fall below peak fluorescence concentrations after
being released into the bulk (Figure 15C). The contrast in formulation (regular vs
PEGylated) and resulting release of liposomes prepared and loaded with identical AO
concentrations exemplifies how liposome formulation influences loading efficiency [31].
Conclusions
With the performed set of experiments, a solid baseline for liposome preparation
using extrusion and sonication along with active and passive loading is established. More
so, the produced liposomes are analyzed and characterized to better understand some of
the key characteristics such as their hydrodynamic radius, size distribution, visual
characteristics, and loading efficiency. Finally, liposomes are confirmed to be loaded at
close to intended concentration with both drug simulating dyes and the drug doxorubicin
both through microscopy and fluorescence spectroscopy.
Sonication and extrusion could produce liposomes composed of either regular or
PEGylated formulation that were suitable for either active or passive loading. Sonication
offers less variety in selecting a desired size of the produced liposomes. Although it was
predictably near 100 nm with both regular and PEGylated lipid membranes, it is
questionable whether liposome diameter can easily be adjusted by modifying sonication
parameters and settings. Although sonication can be used to prepare liposomes with
minimal effort and in short periods of time, size distribution is not predictable, and
quality often suffers. Consistently extrusion provides better size distribution (inferred
from a lower PDI) than sonication prepared with identical lipid composition. Extrusion
also offers the added benefit of offering more control pertaining to the sizing of
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liposomes produced by allowing selection of pore sizes in the polycarbonate membranes
used for extrusion. Finally, extrusion is generally recognized as a gentler method of
preparation, as sonication can easily damage fragile cargo and other membrane
components.
Sonication and extrusion have been extensively used and continue to be used as
they have a proven record of reliably producing liposomes. However, there are aspects to
be further improved, such as time commitment and effort, expenses, and scale of
production, all while preserving quality and reliability. In this light, as liposome research
gathers traction and realizes greater application, developments are constantly being made
to address these concerns. A new technique developed by our lab [42] and described in
the next chapter offers simultaneous production, loading, and purification of liposomes in
a matter of hours.
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Abstract
Liposomes are spherical-shaped vesicles that enclose an aqueous milieu
surrounded by bilayer or multilayer membranes formed by self-assembly of lipid
molecules. They are intensively exploited as either model membranes for fundamental
studies or as vehicles for delivery of active substances in vivo and in vitro. Irrespective of
the method adopted for production of loaded liposomes, obtaining the final purified
product is often achieved by employing multiple, time-consuming steps. To alleviate this
problem, we propose a simplified approach for concomitant production and purification
of loaded liposomes by exploiting the Electrodialysis-Driven Depletion of charged
molecules from solutions. Our investigations show that electrically-driven migration of
charged detergent and dye molecules from solutions that include natural or synthetic lipid
mixtures leads to rapid self-assembly of loaded, purified liposomes, as inferred from
microscopy and fluorescence spectroscopy assessments. In addition, the same procedure
was successfully applied for incorporating PEGylated lipids into the membranes for the
purpose of enabling long-circulation times needed for potential in vivo applications.
Dynamic Light Scattering analyses and comparison of electrically-formed liposomes with
liposomes produced by sonication or extrusion suggest potential use for numerous in
vitro and in vivo applications.
Introduction
Liposomes are spherical vesicles that enclose an aqueous interior cavity protected
by a unilamellar or multilamellar shell made of lipids, and the exploitation of their
features has enabled the development of myriads of scientific and biomedical
applications [1–6]. The liposome membrane is made of lipids commonly found in cell
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membranes, and their compositions may be adjusted by addition of specific lipids and
sterols to better simulate the lipid partition of a particular membrane host. Such
mimicking provides a simplified experimental system for surveying transport properties
of membranes [4,7]. More fundamental exploration options are presented by the ability to
reconstitute membrane receptors directly into membranes [8,9] or to functionalize the
membrane surface by chemical addition of specific recognition elements [10–12].
Another important set of applications of liposomes originates in their ability to function
as carriers for ions and molecules. Liposomes may transport hydrophilic, water-soluble
cargo within their aqueous inner volume, and non-polar compounds embedded within the
hydrophobic core of the membrane. These excellent transport capabilities led to the idea
of using liposomes for transport and delivery of drugs to diseased organs and tissues in
the human body [13]. The ability to adjust the physio-chemical properties of liposomes
for drug delivery purposes is greatly exemplified by their FDA-approved clinical
application for cancer therapy [14,15]. Liposome PEGylation significantly improves their
circulation time by preventing recognition by the reticuloendothelial system (RES) /
mononuclear phagocyte system (MPS) [16–18], while a small size enables selfaccumulation into solid tumors by the Enhanced Permeability and Retention (EPR) effect
[19–21]. Active loading of drugs such as doxorubicin enables the achievement of high
local drug concentrations, greatly reducing systemic distribution by self-accumulating at
the tumor site [22].
All production methods of liposomes used as carriers employ liposome
preparation and loading. Irrespective of the production approach adopted, liposome
preparation relies on the self-assembly of lipids, which is driven by their amphiphilic
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nature and interactions with water. Hydration from thin lipid films usually leads to the
formation of multilamellar liposomes, which are further down-sized and rendered
unilamellar by extrusion or sonication [23–26]. In this case, passive drug loading may be
realized by direct addition to the hydrating solution, while active loading by
electrochemical gradients may be achieved after liposome formation [27,28]. In a
different approach, liposome preparation is achieved by further dilution of a solvent
utilized to solubilize the lipids, which may be performed by organic solvent injection
[29–31] or detergent removal [32–36]. These methods are well established, and each one
has advantages and disadvantages with respect to equipment requirements, achievement
of desired size, loading protocol and efficacy, and time. A major bottleneck common
among multiple production methods is the time needed to complete the procedures and
obtain loaded liposomes devoid of unloaded cargo in the bulk.
To alleviate this problem, we propose producing loaded and purified liposomes by
Electrodialysis-Driven Depletion (EDD) of detergent. Detergent removal has long been
understood to create bilayers [33,37] and established as a method for preparing
unilamellar liposomes [33–36,38]. Upon solubilizing lipids with a detergent, a mixed
micelle formation consisting of detergent and lipids appear. Removal of the detergent
results in fusion of micelles and bilayer disk formation. As the disk becomes larger, it
will curve to minimize edge circumference to reduce hydrocarbon tail exposure to
aqueous solution and eventually enclose to form a bilayer sphere, eliminating exposed
edges [39,40].
Based on this body of evidence, we hypothesized that electrophoresis may lead to
rapid depletion of ionic detergents from detergent-lipid mixtures and liposome formation.
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In addition, we anticipated that charged molecules intended as cargo may be trapped
inside the formed liposomes before being cleared from the bulk by the action of the
electric field. Our experimental results strongly support the applicability of EDD for fast
liposome formation, loading, and purification.
Materials and Methods
Asolectin (Aso, Sigma-Aldrich, St. Louis, MO, USA), cholesterol (Chol, SigmaAldrich), brain sphingomyelin (SM, Avanti Polar Lipids, Alabaster, AL, USA), 1,2distearoyl-sn-glycero-3-phosphocholine (DSPC, Avanti Polar Lipids), and 1,2-distearoylsn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG,
Avanti Polar Lipids) were purchased either in powder or chloroform-solubilized form.
The powder lipids were solubilized in chloroform, mixed with the other lipids at the
desired ratios in a glass vial, and had the solvent removed by being placed under vacuum
for at least 12 h. Formed lipid films not used immediately were stored in a freezer at -20
°C. The precursors to all liposome preparations were the dried lipid films prepared from
mixture of lipids at dry-weight ratios specified in the results section. KCl (ThermoFisher
Scientific, Waltham, MA, USA), a stock solution of 1M HEPES (Sigma-Aldrich) of pH
7.4, and cholic acid (CA, ThermoFisher Scientific) were used to prepare buffered ionic
solutions (20 mM KCl, 5 mM Hepes) with or without addition of acridine orange (AO) or
rhodamine 6G (R6G) (both from ThermoFisher Scientific) at 1 mM final concentration.
The emission spectrum of each dye was determined with a FluoroMax4
spectrofluorometer (Horiba Scientific, Piscataway, NJ, USA) set in emission mode. The
same instrument was used to establish the AO self-quenching plot, monitor AO and R6G
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migration under exposure to electric field, and measure the release kinetics of dyes
loaded into liposomes.
The electrodialysis-driven depletion (EDD) experiments employed a traditional
use of the ElectroPrep Electrodialysis System (product #: 74-1196, Harvard Apparatus,
Holliston, MA, USA), which was also adapted for real-time assessment of dye migration
from the Ultra-Fast Dialyzer chamber (Harvard Apparatus) under exposure to electric
fields in order to establish the time required to complete dye depletion from the chamber.
The modified experimental setup (Figure 16) included the ElectroPrep Electrodialysis
System completed with a custom fluidic system which continuously re-circulated the
solution from either reservoir with a multi-port Gilson MiniPuls 3 peristaltic pump
(Gilson Inc., Middleton, WI, USA) and fed a constant-volume flow cell (cuvette) for
monitoring of fluorescence with the spectrofluorometer. Specific emission of each dye
was measured in kinetics mode at 0.1 s integration time and a sampling rate of six
samples/minute. The solution in the dialysis chamber mounted in the insulating
separation wall was the only conducting pathway between the reservoirs. Consequently,
charged molecules migrated from the dialysis chamber into the corresponding reservoir
as dictated by the electrophoretic force. The Pt electrodes of the ElectroPrep
Electrodialysis System were wired to a VWR Power Source 300V electrophoresis power
supply (VWR International, Radnor, PA, USA) set to constant current, and the solutions
in the reservoirs were continuously stirred with magnetic stir bars.
Liposome production by EDD comprised hydration and solubilization of lipid
mixtures in 1 mL ionic solutions containing 2% (w/v) CA. To aid homogenization, the
samples underwent a brief sonication (10 s) in a bath sonicator (Fisher Scientific),
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followed by 10 min heating at 75 °C and another brief sonication. After solubilization,
the solutions were transferred into the double sided Ultra-Fast Dialyzer chamber
equipped at both ends with polycarbonate membranes (10 nm pores, Harvard Apparatus),
and mounted in the insulating separation wall of the ElectroPrep Electrodialysis tank
filled with electrolyte solutions.

Figure 5.
Experimental setup for liposome production by electrodialysis-driven
depletion (EDD) and fluorescence monitoring. The custom setup includes the
electrodialysis tank (ElectroPrep Electrodialysis System), an Ultra-Fast Dialyzer
chamber, and a microfluidic setup to recirculate the solutions through a constant
volume fluorometer cuvette for real-time fluorescence measurements. This specific
setup describes migration and quantification of an anionic dye transferred from the
dialysis chamber to the left reservoir. The solutions in the two reservoirs were
continuously stirred with magnetic bars. The diagram is not to scale.
Liposome preparation by sonication was performed with a Misonix S-4000 probe
sonicator (Misonix, Farmingdale, NY, USA) equipped with a micro-tip. The lipid
mixtures (with, and without dyes) were hydrated in warm electrolyte solutions, then
placed into small glass vials and sonicated on ice for 15 min in manual mode at 25%
amplitude, and a power transfer of 6–7 W.
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For extrusion, the lipid films in the glass vials were slowly hydrated for a few hours at 45
°C. To complete hydration and homogenize the mixture, the hydrated samples underwent
four freeze/thaw cycles. The liposomes were extruded at 70 °C with an Avanti Polar
Lipids extruder equipped with 200 nm polycarbonate filters for a total of 61 passes.
Imaging was completed with an Olympus IX71 fluorescence microscope (Olympus
Scientific Solutions Americas Corp, Waltham, MA, USA) equipped with filter sets
specific for the used dyes. The release of encapsulated dyes was monitored from the
fluorescence changes elicited by membrane permeabilization with 0.5% Triton X-100
(Sigma-Aldrich) [41,42]. A similar procedure was utilized to assess the unilamellarity of
EDD-produced liposomes by inducing permeabilization with the pore-forming toxin
lysenin (Sigma-Aldrich).
For comparison between the three distinct production methods, liposomes were
characterized by dynamic light scattering (DLS) with the Zetasizer Nano ZS (Malvern
Panalytical Inc., Westborough, MA, USA) for determination of average hydrodynamic
diameter and size distribution (PDI, polydispersity index) at room temperature. For each
liposome sample we analyzed three sets, with each set consisting of 13 consecutive runs.
Each set provided the corresponding average diameter and PDI, from which we
calculated the mean values and standard deviations.
Results and Discussions
Dye Separation by Electrodialysis
Successful separation by electrodialysis requires the detergent and dye molecules
to possess an effective electric load. The used detergent (CA) is acidic (pKa = 4.8 [43])
and completely ionized near neutral pH; although many of the common fluorescent dyes
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are also charged for a large range of pHs, we did not know how long they would take to
migrate from the dialysis chamber to the reservoirs upon exposure to an external electric
field. A potential issue with the electrical conditions is that the electrical currents may
lead to redox reactions at the electrodes (i.e., H+ and HO− production, as well as other
products that may also lead to undesired side reactions in solutions), and an increased
temperature through the Joule effect. pH changes may affect the ionization status of the
molecules and their migration, and they may also modulate the fluorescence of the dyes.
To alleviate such potential issues, we sought to reduce the electrical currents in order to
prevent major temperature and pH changes. While this may be simply realized by
reducing the applied voltage, such an approach will also diminish the magnitude of the
electrophoretic force, which may lengthen the time required for migration. After some
experimentation, we established that the 20 mM KCl/5 mM HEPES (pH = 7.4) led to
minor variations of temperature of the bulk ~2 °C) and pH in the dialysis chamber (~0.3
units) at 75 mA constant current applied for 45 min.
To determine the time required for dye migration, we loaded the electrodialysis
chamber with 1mM of AO or R6G. The electrodialysis tank reservoirs were filled with
dye-free ionic solutions and dye migration was estimated by employing the fluidic system
described in the Materials and Methods section. The evolution of the fluorescence in
reservoirs was estimated from kinetics measurements by employing the flow cell and the
fluorometer. The wavelengths for excitation/emission were set apart for each of the dyes
(AO: 485 nm/530 nm, R6G: 528 nm/550 nm), with a 1 nm slit for both excitation and
emission. The power supply was set to 75 mA constant current, and the fluorescence
measurements started ~10 s after applying the voltage. Both dyes started migrating from
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the chamber shortly after application of the electric field and the fluorescence
monotonically increased until reaching a plateau indicative of migration completion
(Figure 17). The kinetics profiles (i.e., the characteristic time) for the dyes were different,
and AO migrated faster than R6G. However, the maximum signal was achieved in less
than 40 min for both dyes, which set a reference time frame for further electrodialysis
experiments.

Figure 6.
Electrodialysis leads to rapid depletion of charged dyes from
solutions. Acridine orange (AO) (a) migrates faster than rhodamine 6G (R6G) (b)
but both are depleted from the dialysis chamber and transferred into the reservoirs
in less than 40 min.
Simultaneous Liposome Formation, Loading, and Purification by EDD
Detergent removal from the lipid-containing mixtures by dialysis drives the
formation of self-enclosed structures [33,44]. We hypothesized that during enclosure, dye
molecules can also be entrapped within the formed liposomes. Therefore, fast and
concomitant liposome formation and loading may be achieved if the detergent and dye
are electrophoretically driven outside the dialysis chamber.
To test this hypothesis, we prepared lipid mixtures (Aso:Chol, 10:4 weight ratio)
in ionic solutions containing 2% (w/v) CA to which 1 mM AO or R6G was added. The
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samples were subjected to electrodialysis at 75 mA constant current for up to 40 min.
Figure 18 shows that simultaneous clearance of detergent and dye molecules leads to
formation of loaded liposomes.

Figure 7.
Microscopy imaging of fluorescent liposomes produced and purified
by EDD. The liposomes are composed of asolectin and cholesterol and are loaded
with AO (left panel) and R6G (right panel). The scale bar is 10 µm.
Production of Long-Circulating Liposomes by Electrodialysis
The rapid clearance of liposomes from circulation constitutes a major roadblock
for in vivo biomedical applications [45–47]. However, substantially improved circulation
times are attained by adjusting the lipid composition of the membrane in order to
minimize the undesired interactions with the defense system of the host. Addition of
PEGylated lipids to the self-assembled membranes is often employed to extend the
lifetime of liposomes in circulation, and such compositions are used for producing
liposomes intended for cancer therapy and other in vivo applications [16–18,46,48,49].
To verify if electrodialysis is suitable for formation and loading of long-circulating
liposomes, we prepared lipid mixtures containing DSPC, Chol, and DSPE-PEG
(8.2:3.8:2.6 weight ratios). The lipids were solubilized in the buffered solution containing
2% CA and 1 mM AO, heated for 20 min at 75 °C, introduced into the Ultra-Fast
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Dialyzer chamber and subjected to a constant current of 75 mA for 20 min. Microscopy
imaging revealed the formation of AO-loaded liposomes (Figure 19) and the good
contrast ratio between liposomes and background suggested successful elimination of
non- incorporated AO.

Figure 8.

Microscopy image of PEGylated liposomes loaded with AO, prepared,
and purified by EDD. The scale bar is 10 µm.

Verification of Dye Loading
There is no doubt that some of the dye present in the solubilization buffer is lost
during the exposure to electrical currents due to migration before being trapped in the
formed liposomes. To provide a rough estimation of the residual AO concentration inside
PEGylated liposomes, we performed a release experiment that employed solubilization of
liposomal membranes by addition of the non-ionic detergent Triton X-100 [41,42]. AO
fluorescence presents self-quenching, i.e., a significant decrease in fluorescence
manifested upon increase in dye concentration over 10 µM [50]. Although the exact

60
mechanisms of self-quenching are not elucidated, it is considered that the intermolecular
interactions occurring at high concentrations lead to a diminished fluorescence emission
[50–52]. If self-quenching concentrations are attained inside liposomes, membrane
solubilization leads to dye dissipation into the bulk, and the decrease in concentration
over time is monitored from the increase in fluorescence [53].
The changes in AO fluorescence intensity recorded upon addition of 100 µL of
5% Triton-X-100 to a 1.0 mL buffer solution containing 20 µL PEGylated liposomes
produced by electrodialysis indicated that the AO concentration inside liposomes attained
self-quenching levels (Figure 20). In addition, the fluorescence continually increased
upon membrane solubilization, indicating that the AO concentration in the bulk did not
fall below self-quenching level.

Figure 20.
AO release from PEGylated liposomes produced, loaded, and purified
by EDD. (a) AO fluorescence indicates self-quenching at bulk concentrations over
10 µM. (b) The sustained release of AO from liposomes solubilized by addition of
Triton X-100 indicates successful loading.
Unilamellar or Multilamellar?
Our next investigation addressed the lamellarity of the liposomes produced by
EDD. Irrespective of the production method, a fraction of the liposomes will have the
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membrane consisting of multiple layers, which may impede their further application for
purposes that require unilamellar liposomes. The fundamental difference between
unilamellar and multilamellar liposomes is the number of lipid layers they consist of.
Determining the number of layers in the membrane is not an easy task and may require
sophisticated instruments and extensive preparatory tasks [54,55]. To answer this
question, we proceeded with exploring the interactions between liposomal membranes
and pore-forming toxins. This approach is based on the significant changes in the
membrane permeability induced by the conductive pathways produced by the poreforming toxins interacting with the target membranes; the leaky membrane leads to the
release of incorporated dyes, which can be assessed by microscopy or fluorescence
spectroscopy. For our investigations we used the prototype pore-forming toxin lysenin,
which introduces large-conductance pores in artificial and natural membranes containing
sphingomyelin [56–59]. However, for relevancy with regards to the membrane thickness,
one may assume that lysenin may not span multiple bilayers [60], therefore the changes
in membrane permeability are specific to unilamellar liposomes. Liposomes consisting of
Aso, SM, and Chol (10:4:4 weight ratio) were produced and loaded with AO by
electrodialysis as described in the previous sections and analyzed by fluorescence
spectroscopy. The release of the dye was monitored from the changes in AO’s
fluorescence upon addition of lysenin (~20 ng) to the cuvette containing 2mL buffer and
100 µL liposomes. As inferred from the recorded kinetics (Figure 6), the release of the
dye started immediately after lysenin addition, and monotonically increased for the total
duration of the record (3,000 s). As anticipated, the lysenin-induced release was slower
than the detergent-induced release since lysenin channels must first interact with the
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target membranes and oligomerize into functional pores to induce release of the dye. The
fluorescence asymptotically approached a steady state, which corresponds to ~80 % of
the total release induced by Triton X-100 addition (Figure 21).
This experiment suggests that most of the target membranes are unilamellar;
nonetheless, this is not irrefutable proof that all the membranes are solely consisting of
lipid bilayers. Unilamellar and multilamellar patches may be present within the same
liposomes, and the unilamellar portion of the membrane may facilitate lysenin-induced
permeabilization and dye release.

Figure 9.
Lysenin-induced permeabilization of sphingomyelin-based liposomes.
The sustained release of AO (~80 % in less than one hour, relative to 100% release
achieved by Triton X-100 addition) suggests that the target membranes are
unilamellar. The dashed line shows the 100% release achieved by Triton X-100
addition.
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EDD Comparison to Extrusion and Sonication
Two well-established methods of liposome preparation are extrusion and
sonication [23], which have been widely and successfully used for decades [61].
Extrusion refines liposomes formed by hydration and self-assembly to render them
unilamellar and adjust their size by passage through membrane filter pores of a particular
size [25,26]. Sonication also generates relatively consistent and evenly distributed
populations of unilamellar liposomes in a short period of time with low effort, although
their size is not easily controlled. However, production of loaded liposomes by either
method requires further purification steps to remove the unincorporated molecules from
bulk. When charged cargo is used for liposome loading, EDD may eliminate the
necessity of further purification and significantly reduce the time required for preparation
of loaded liposomes. To further assess the quality of liposomes prepared by the three
different methods (extrusion, sonication, and EDD), we compared their physical
characteristics by DLS. The three experiments utilized identical lipid compositions (10:4
mass ratio of Aso to Chol) and ionic solutions; only electrodialysis comprised addition of
CA for solubilization. For consistency, all the lipids were first mixed in chloroform,
placed in glass vials, vacuumed overnight for solvent removal, and the formed thin films
were hydrated for 2 h at 45 0C. Liposomes were prepared by extrusion, sonication, and
EDD as described in the methods section. DLS analysis (Figure 22) indicated that
extrusion provided an average diameter of 259.6 ± 2.4 nm and the narrowest size
distribution with a PDI of 0.077 ± 0.029. Liposomes obtained by sonication presented a
significantly smaller average diameter of 114.2 ± 1.8 nm with a larger size distribution,
having a PDI of 0.250 ± 0.013. EDD led to formation of liposomes characterized by an
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intermediate size, with an average diameter of 134.8 ± 0.7 nm and a PDI of 0.214 ±
0.011.
A simple comparison between the three methods shows the most uniform size
distribution is achieved by extrusion. This method also enables controlling the average
diameter of the liposomes by choosing appropriate membrane filters, which are available
in a large range of pore sizes. Both sonication and EDD are fast, simple, and provide
satisfactory size distribution of produced liposomes. In both cases however, the size of
the produced liposomes is not easily adjusted from experimental conditions.
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Figure 22.
Dynamic light scattering characterization of liposomes produced by
extrusion (a), probe sonication (b), and EDD (c). Each plot shows the mean intensity
percent ± SD (n = 3) determined as a function of diameter.
The physical characteristics of the EDD-produced liposomes together with the
ability to utilize lipid compositions that improve their circulation time suggest that they
are suitable for a large variety of scientific and biomedical applications [62]. An
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advantage of the EDD method over others is its ability to simultaneously form, load, and
separate liposomes from the non-incorporated cargo, therefore significantly reducing the
time needed for purification. However, beside the necessity of using charged detergents
and dyes, liposome production by EDD has other potential limitations. Changes in pH
and solution compositions during electrodialysis may alter the physical and chemical
properties of the molecules (i.e., ionization state, or fluorescence). This is particularly
concerning if the cargo molecules are heavily reliant on such properties for their intended
purpose and efficacy. A simple solution to address this problem was the use of a low
ionic strength electrolyte solution. Such solutions may lead to osmotic balance issues, but
they may be mitigated by including neutral molecules (i.e., sugars) in the solutions to
ensure iso-osmolarity. Although EDD is similar to other solvent-removal methods
(including detergent removal by simple dialysis), we do not have an estimate of the
amount of detergent left in solutions or membranes. We successfully tested several
lipid/dye compositions but one universal setting for successful EDD might be elusive.
Therefore, pretreatment conditions, such as temperature and solution agitation, as well as
solution and electrical conditions may need to be tailored to other lipids and cargo used
for EDD preparation of loaded liposomes.
Conclusion
In summary, EDD may be employed for fast and cost-effective production of
loaded and purified liposomes. The size and distribution quality of the liposomes
attainable with EDD are comparable to extrusion and sonication. Further investigations of
the various settings and parameters and their influence on liposome formation and
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loading may provide a better understanding of the limitations and full potential presented
by this method for scientific and biomedical applications.
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CHAPTER FOUR: CONTROLLED RELEASE FROM PHOTOCLICK AND PHSENSITIVE LIPOSOMES
Introduction
The use of liposomes as enclosed, protective structures, capable of delivering
their cargo is often marred by their passive and uncontrolled release [1-3]. Encapsulation
and preservation of payload is one of the major purposes of liposome technology,
however experimenters and producers must often compromise. One must choose between
leaky liposomes that release too quickly, or liposomes made to avoid leakage completely,
resulting in very slow and insignificant release. Ideally, release would occur only at a
desired time, however controlled release of cargo from liposomes is an unmet challenge
that can limit their use in many applications, particularly in the realms of scientific
research and medical use [4, 5].
A key area of interest pertaining to controlled release involves chemotherapeutic
delivery for the treatment of cancers [6, 7]. The slow passive leakage of
chemotherapeutics within a few weeks after accumulation at tumor sites is often
ineffective in stopping the rapid division of cancer cells [1]. To address this issue, the
past decades have investigated numerous bioengineering approaches and stimuli for
inducing drug release from liposomes in a localized and efficient manner [2].
Investigations on controlled release from liposomes have ranged from using mild
hyperthermia [8, 9], photo-activation [10, 11], focused ultrasound [12, 13], nanoparticles
and molecules embedded or co-loaded with the main cargo to aid in liposome leakage
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upon near-infrared [7, 14] or magnetic field exposure [15-17], as well as pH change to be
triggered by external microenvironment conditions of tumor tissue [18, 19]. Although the
intended outcome of content release is achieved, the efficiency and degree of release is
questionable; as a matter of fact, no method of controlled drug release from liposomes is
included in current clinical practices.
In addition to the proposed mechanisms pertaining to cargo release upon
stimulation by radiation (usually UV, VIS, and IR), an attractive subcategory is presented
by the utilization of photosensitive lipids endowed with additional chemical bonding
capabilities upon radiation exposure. In this endeavor, photopolymerizable lipids allow
successful control of membrane permeability. Upon UV or visible light stimulation,
photosensitive lipids undergo covalent bonding and polymerization [10, 11, 20, 21]. The
loss of fluidity resulting from the de novo created bonds translates into a significant
increase in permeability, which allows the transport of ions and molecules through the
otherwise impermeable membranes [22]. Apparently, this process is augmented by the
segregation of photopolymerizable lipids into domains (rafts), which promotes radiationinduced polymerization and leads to increased membrane permeability [10, 22].
Considering PhotoClick membrane components have been insufficiently studied for use
in photo-responsive liposomes, we decided to further investigate their potential in this
regard. PhotoClick chemistry involves the activation of diazirine moieties in specially
modified sphingosine and cholesterol to become activated upon exposure to UV light at
approximately 365 nm [23]. Photoactivation leads to diazirine reactions, resulting in a
covalently reactive carbene (Figure 23) [24]. Furthermore, sphingosine and cholesterol
are understood to accumulate in lipid rafts in membranes [25-28]. This suggests increased
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likelihood of crosslinking between these components considering their increased
proximity in such areas, making them an excellent candidate for being used in the
intended manner.

Figure 10.
PhotoClick reaction of diazirine. The diazirine moiety on PhotoClick
sphingomyelin, one of the UV sensitive components used in our liposomes, releases
nitrogen and results in reactive carbene formation upon UV exposure. Carbene
readily covalently bonds, allowing for crosslinking in the membranes, and leading to
permeabilization. Similar chemical process occurs in PhotoClick cholesterol, the
other UV sensitive component used.
Although the response to visible and UV light has been demonstrated to induce
release from photosensitive liposomes made with other photopolymerizable lipids [21,
29], an obvious issue remains when considering their application for the use as
chemotherapeutic delivery vehicles to tumors. Light and UV are not very capable of
penetrating tissue. Deep seated tumors are therefore not going to benefit from
photosensitive liposomes, as light and UV will not be capable of triggering release of
loaded chemotherapy. However, O’Brien et al. reported that some liposomes made with
photopolymerizable components are also X-ray responsive [30]. This prompted us to
investigate the possibility that liposomes composed with PhotoClick components are also
responsive to X-ray irradiation. This would be a momentous advancement in controlled
release from liposomes, as an actinic beam utilized for radiotherapy can be used to also
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serve as a controlled, effective, and highly localized trigger for release of
chemotherapeutics [31, 32]. Although the postulated benefits of concomitant radiation
and chemotherapy are still unclear due to the lack of sufficient investigations, evidence
suggests such an approach has the potential to treat tumors at a significantly higher
efficiency than either treatment alone [33-36]. Furthermore, simultaneous radiochemotherapy is strongly limited by its combined toxicity [35, 37]; targeted release of
local chemotherapy using liposomes capable of release upon X-ray exposure would have
the potential to significantly reduce the toxicity of systemic chemotherapy treatment
while improving the overall clinical outcome.
Our further investigations looked into pH sensitive liposomes, which we
redesigned to be triggered to release their payload by pH changes induced by irradiation.
Stealth liposomes sensitive to pH changes have been long foreseen as candidates for drug
delivery into tumors [38-42]. Stealth liposomes, already utilized for drug delivery,
present a reduced uptake by cells of the reticuloendothelial system (RES)/ mononuclear
phagocyte system (MPS). This results in a long circulation median lifetime [43, 44] and
accumulation into tumors by the enhanced permeability and retention (EPR) effect [45,
46]. The added pH sensitivity creates the means to release an incorporated drug upon pH
variation (usually increase of acidity), therefore ensuring delivery. The primary design of
these specialized vehicles was based on the hypothesis that pH decreases dramatically
inside a tumor; however, this decrease is not uniform, and it has been proven to be rather
modest [47]. Therefore, controlling the pH of the environment by external stimuli may
add the benefit of controlled drug release from pH sensitive liposomes.
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Most pH-sensitive liposome formulations described in the literature are prepared
with unsaturated phospholipids in combination with mildly acidic amphiphiles, and their
ability to deliver incorporated drugs upon decreasing pH is well documented [18, 38, 39,
41, 42]. Since the ability to release the drug from such vehicles directly depends on pH, a
mechanism to control the local intra-liposomal pH is required. In this endeavor, we
sought a mechanism by which acidification would be produced upon interaction with
ionizing radiation, thus allowing concomitant radio and chemotherapy.
To achieve our scientific goals, we propose using organic halogens to induce
acidification upon X-ray exposure to gain local pH control. Chemical changes upon
irradiation of organic halogens were an important topic in the 50s and 60s [48-56], when
scientists were looking for simple, meaningful ways to determine doses of radiation.
Although the advent of solid-state physics and electronics led to the almost total
abandonment of such approaches, the scientific explorations for dosimetry purposes led
to new knowledge, useful for our purposes. Many organic halogen compounds liberate
the corresponding halogen acid when irradiated in water solutions [48-56]. Although the
exact mechanism is not known, there is evidence that the action is indirect, through
radicals produced from water upon irradiation. The chief ionizable product formed after
exposure to X-ray was demonstrated to be the halogenated acid. From all organic
halogens suitable for our purpose, we focused our attention on bromal hydrate; since the
1950s, water solutions of bromal hydrate have been proposed to be used as radiation
dosimeters based on HBr release upon irradiation [53].
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Materials and Methods
Lipids, Loading Molecules, and Solutions
The lipids used for liposome preparation included 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC, Avanti Polar Lipids), cholesterol (Chol, Sigma-Aldrich),
sphingomyelin (SM, Avanti Polar Lipids), PhotoClick sphingosine (P-SM, Avanti Polar
Lipids), PhotoClick cholesterol (P-Chol, Avanti Polar Lipids), phosphatidylethanolamine
(PE, Avanti Polar Lipids), and oleic acid (OA, Avanti Polar Lipids). Lipids were
purchased either in powder or chloroform-solubilized form. The powder lipids were
solubilized in chloroform as concentrated stock solutions, mixed with the other lipids at
the desired ratios in glass vials (amber, and covered with Al foil for all light sensitive
compounds), and had the solvent removed by being placed under vacuum at room
temperature for at least 12 h. The formed lipid cakes were stored in the freezer until
further use. Structural details of the used lipids are presented in Figure 24.
Electrolyte buffered solutions were prepared with KCl, NaCl (ThermoFisher
Scientific), and HEPES (additions from a 1M stock solution of pH 7.4, Sigma-Aldrich).
Calcein (CAL, ThermoFisher Scientific) and cisplatin (CIS, ThermoFisher Scientific)
were diluted to desired concentration in the hydrating buffers for passive loading. For the
preparation of liposomes intended for active loading with doxorubicin (DOX, SigmaAldrich) we used a 150 mM citrate buffer made from sodium citrate dihydrate and citric
acid (both from Fisher Scientific); the pH was adjusted to pH 4.24 by adding small
aliquots of 1 M HCl. Anhydrous bromal (TCI America) mixed with water was recrystallized under vacuum, hydrated to 1M final concentration, then further reduced to
150 mM concentration and stored in a sealed amber container in the refrigerator. KCl
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solutions (135 mM, pH 7.2) as well as stock solutions of HCl (concentrations ranging
from 0.1 mM to 100 mM) were used for investigations of pH-sensitive liposomes. All the
other common chemicals were purchased from various producers and prepared according
to their recommendations.
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Figure 24.
Lipid components used in the production of liposomes used for
investigations on controlled release. Cholesterol (Chol) and 1,2-distearoyl-snglycero-3-phosphocholine (DSPC) were used for both UV/X-ray and pH sensitive
liposomes. PhotoClick sphingosine (P-SM), PhotoClick cholesterol (P-Chol), and
sphingomyelin (SM) were used specifically for UV/X-ray sensitive liposomes (DSPEPEG was used in one variation of PhotoClick composed liposomes with DOX
loading. Phosphatidylethanolamine (PE), oleic acid (OA), and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPEPEG) were used specifically for pH sensitive liposomes. UV/X-ray sensitive
components are outlined in dashed blue line; the dotted red line outlines the
components used for preparation of pH sensitive liposomes.
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Liposomes Preparation
Slow hydration of lipids in the desired buffered solutions (with or without cargo)
was achieved by adding the solutions over the lipid cakes in sealed glass vials, after
which the mixtures were gradually heated from 45 °C to 68 °C over a few hours. The
large aggregates that were easily visible in the hydration vials were dispersed by either
brief sonication (5 seconds in a bath sonicator, Fisher Scientific) or a few cycles of
freezing/thawing.
Liposome preparation was performed exclusively by employing the extrusion
technique [57-59]. An Avanti Polar Lipids extruder with a proper set of polycarbonate
filter membranes (pore size of 400 nm and 800 nm, as indicated for each specific
experiment) was placed on a hot plate preheated to ensure a temperature of the extruder
body greater than the transition temperature of the used lipids (generally, a temperature of
70 °C was sufficient for all the experiments). To avoid any potential interactions between
the photo-sensitive lipids and light, the syringes were covered with aluminum foil during
extrusion. The syringes were filled with hydrated lipid mixtures for both passive and
active loading of dyes or drugs, as detailed next. Each extrusion protocol comprised at
least 41 passes through the polycarbonate membrane.
Liposome Loading and Purification
Passive loading of the liposomes was achieved by adding the cargo at the
intended concentrations mixed into hydration buffer; after extrusion, the nonincorporated load was removed by extensive dialysis in cassettes against 0.5 L – 2 L of
dye-free buffered solution. For active loading of DOX, first an electrochemical gradient
was created by dialysis-exchange of the acidic external buffer with a neutral or near-
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neutral one. After buffer exchange, active loading was initiated by addition of 125 µM
DOX to the bulk. The loading process lasted for at least 48 hours, after which the
unloaded DOX was removed by dialysis against a DOX-free buffered solution (neutral or
near-neutral pH).
Fluorescence and Spectral Characterization
Fluorescence spectroscopy was utilized for establishing the self-quenching plots
of CAL and DOX, and for determining the kinetics of the drug release upon liposome
exposure to physical and chemical stimuli. For these purposes, we utilized a FluoroMax4
spectrofluorometer (Horiba) set in either emission or kinetics mode. For these release
characterizations, the normalized efficiency EN was calculated by considering the
fluorescence of the sample before exposure (F0), the fluorescence of the sample after
exposure and at different time intervals (F), and the maximal fluorescence (F100)
determined upon total release of the considered dye from liposomes in the presence of
Triton X-100 (Sigma Aldrich) [60]. This was used to analyze release data at multiple
time points. For relative release efficiency (ER), the initial fluorescence (F0) was not
subtracted to allow better visual comparison of controls and experimental samples in the
single point bar graphs used. The release efficiency is given in percent. The formulas
used for release efficiency are:
EN% = 100 ☓ (F-F0)/(F100-F0)

or

ER% = (F/ F100) ☓ 100

Since CIS is non-fluorescent, we adopted the optical absorption quantification
method from prior work reported elsewhere [61-63]. For establishment of a CIS
concentration standard curve o-phenylenediamine (OPDA, Fisher Scientific) and
dimethylformamide (DMF, Fisher Scientific) were used to complex with CIS for optical
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absorption analysis with a Varian Carry 5000 spectrophotometer. A stock solution of CIS
was obtained by dissolving 10 mg CIS in 100 mL potassium phosphate buffer (135 mM,
pH 7.2) at 65° C. Working standard solutions were prepared by using 1 mL OPDA at 1.4
mg/mL in DMF and further filled with phosphate buffer to a total volume of 3 mL. The
solutions were heated in a water bath at 100° C for 10 minutes to develop the green color.
After cooling at room temperature, the final volume was adjusted to 10 mL with DMF
and the absorption at 704 nm was determined with the spectrometer [61-63]. The reaction
responsible for CIS complex formation is summarized in Figure 25.

Figure 11.
Optically absorbing complex formation of Cisplatin. Reaction with ophenylenediamine (OPDA) and dimethylformamide (DMF) results in increased
absorbance at 704 nm.
UV and X-Ray Irradiation
Preliminary testing under UV irradiation conditions was completed with a highly
directional UV LED (SETI, 365 nm). The LED was mounted into the lid of a
spectrometer cuvette and powered from a custom constant current generator; the
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approximate UV power emitted by the LED was only 0.5 mW. X-ray irradiation of
samples was performed with a Quantum CS-1 X-ray system, equipped with a Quantum
40kW/125 kVp "Q-Vision" high frequency radiographic generator; the irradiation
conditions are detailed in the results and discussions section.
Results and Discussions
Self-Quenching of Calcein and Doxorubicin
The emission spectra of CAL and DOX solutions as a function of concentrations
were measured with the Fluoromax4 fluorometer set in emission mode for excitation
wavelengths of 495 nm (CAL) and 470 nm (DOX). The magnitude of the emission was
determined from the recorded spectra at 520 nm for CAL, and 570 nm for DOX. The
excitation and emission slits were set at 1 nm. Both dyes presented a concentrationdependent increase in fluorescence in the low concentration range (Figure 26). CAL
reached a maximum in fluorescence at around 20 µM, while DOX achieved the
maximum fluorescence at around 100 µM. However, both dyes encountered a massive
concentration-dependent fluorescence decrease over these concentration values, specific
to self-quenching [64, 65]. This behavior points out the basic principles for the
determination of dye release from fluorescence measurements; liposomes loaded with
dyes at high concentrations will present a low fluorescence owing to self-quenching [66]
(Figures 26 A and B). However, the destabilization of the membrane leads to an increase
of membrane permeability, allowing loaded dyes to leak out. The significant dilution
upon dye release from permeabilized liposomes leads to a prominent increase in
fluorescence. This procedure also enables fast determination of maximum loading; fast
destabilization of the membrane with detergent (i.e., Triton X-100, Figures 26 C and D)
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leads to 100% release of the loaded dye, which may be further used to assess the efficacy
of specific release upon membrane destabilization by physical or chemical stimuli.

Figure 12.
Self-quenching of CAL and DOX, followed by detergent induced
release measurements from loaded liposomes. We established maximum
fluorescence concentration for CAL of about 20 µM (A) and DOX of about 100 µM
(B) characterizing their concentration dependent quenching behaviors. Maximum
release of CAL (C) and DOX (D) was induced by Triton-X 100 addition, showing
loaded and purified liposomes in dye/drug free buffer.
For the preparation of PhotoClick liposomes, DSPC, Chol, SM, P-Chol, and PSM have been dissolved in chloroform at a mass ratio of 10:1:2:1.2:0.8. The mixture was
vacuum dried for 48 hours and the resulting lipid films were hydrated with 135 mM
NaCl, 20 mM HEPES (pH 7.2), and 30 mM CAL (self-quenching concentration). The
final concentration of DSPC in the hydration buffer was 10 mg/mL. A control sample
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consisted of DSPC, Chol, and SM only (10:2:4 mass ratio). After hydration, 800 nm
liposomes were produced by extrusion (41 passes) through stacked polycarbonate filters
and the non-incorporated CAL was removed by overnight cassette dialysis against 1 L of
dye-free buffered electrolyte solution. The samples were stored in amber vials at 4 °C
until use.
In order to identify PhotoClick responsiveness of the liposomes containing P-SM
and P-Chol in their membrane, we performed a preliminary test that employed CAL
release upon exposure to the UV light (365 nm) provided by the LED. The fluorometer
was set in kinetics mode (Ex/Em: 495/520 nm), 1 s integration time, with the antiphotobleaching option activated, and 10 s sampling time. Three cuvettes were filled with
1.9 mL buffered electrolyte solution and 100 µL liposomes. The sample cuvette
contained PhotoClick liposomes, while the control comprised liposomes made without
PhotoClick components. Another control containing PhotoClick liposomes was set for
measuring the 100% CAL release upon addition of 50 µL of 5% v/v Triton X-100; the
relative release efficacy was determined for the sample and control liposomes (Figure
27).
Upon exposure to the UV light from the UV LED, CAL quickly started leaking
out from the liposomes, as indicated by the increasing fluorescent signal. However,
negligible leakage was determined from the UV-exposed liposomes lacking PhotoClick
components, suggesting that the PhotoClick components are needed to render liposomes
sensitive to UV radiation. UV exposure initiates CAL release from PhotoClick liposomes
and results in approximately 70% release of the incorporated dye in less than one hour.
Seeing the sigmoidal trend of CAL release likely suggests a multistep or cooperative
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process in membrane permeabilization. Upon UV exposure, the diazirine groups within
the PhotoClick sphingosine and cholesterol are photo-activated, resulting in the formation
of reactive carbene [24]. This reactive species results in formation of covalent
crosslinking among membrane components, resulting in a loss of membrane fluidity and
allowing the leakage of cargo. It is worth mentioning that our results suggest that
covalent crosslinking occurs without any need for proteins embedded in the liposome
membrane, and this result may be explained based on the lipid self-organization in lipid
rafts [26, 67]. The particular composition of the membranes includes SM and Chol,
which are known to segregate in SM-rich domains (lipid rafts) [27, 28]. The local high
density of bonds prone to crosslinking possibly promote covalent bonding without the
necessity of membrane proteins; nonetheless, it is not clear if the leakage occurs through
the more rigid domains resulted after crosslinking or at the edge between the rigid rafts
and the more fluidic bulk phase [68].
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Figure 27.
UV induced release of CAL from liposomes. 100 µL of CAL loaded
PhotoClick liposomes exposed to UV light resulted in ~70% release. Comparatively,
liposomes lacking PhotoClick components showed negligible release (~1%) over the
time span measurements were taken. 100% release was achieved by treating
PhotoClick liposomes with Triton X-100.
Calcein Release from PhotoClick Liposomes Upon X-ray Exposure
As observed, UV exposure elicited a significant release of CAL in comparison to
the control lacking PhotoClick components. Although this may find immediate in vitro
applications, a prominent shortcoming of using UV to trigger release in liposomes
involves the simple fact that UV light is not capable of significant tissue penetration.
Many tumors needing drug delivery are deeply seated within the body; in this respect, Xray has the benefit of not only being able to penetrate deeply into tissue, but also offer a
major improvement with regards to local and loco-regional control and better clinical
outcome in combination with chemotherapy [36, 69, 70]. Concomitant application of
chemotherapy and radiation have been shown to significantly improve destruction of
tumor tissue, however, it is limited by an increased toxicity [35, 37]. Local release of
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chemotherapy from liposomes triggered by X-ray radiation could allow for highly
localized concomitant radiation and chemotherapy treatment, compounding the efficacy
of tumor destruction, while reducing the immense stress on the body resulting from
systemic chemotherapy and simultaneously added radiotoxicity.
Although it is shown that PhotoClick liposomes respond to UV light, there is no
evidence of PhotoClick lipids having sensitivity to X-ray radiation. However, according
to O’Brien et al, photopolymerizable lipids (which are similarly responsive to UV light)
also respond to ionizing radiation (i.e., X-ray) [30]. Prompted by these prior findings, we
tested whether the PhotoClick liposomes also respond to X-ray radiation, which may
prove fruitful for future biomedical applications of this technology for drug delivery and
cancer therapy. To answer these questions, we prepared 800 nm PhotoClick liposomes
with lipid compositions identical to the previous experiment and filled them with 30 mM
CAL solubilized in a buffer containing 50 mM KCl and 50 mM Hepes (pH 7.2). The Xray exposure was performed by applying a succession of 20 pulses from the X-ray
equipment (0.125 MeV, 320 mA). The fluorescence of the sample and control liposomes
was recorded before and after irradiation, and the maximum (100%) relative efficacy
determined based on the maximum release recorded for the non-irradiated PhotoClick
sample solubilized by addition of 100 µL 5% v/v Triton X-100 (Figure 28). Our results
indicate that approximately 60% of the CAL dye was released from the exposed
PhotoClick sample in less than one hour. Within the same time interval, the exposed
control showed negligible release, suggesting that the PhotoClick components are
essential to initiating and sustaining cargo release from liposomes upon X-ray exposure.
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Figure 13.
Normalized release percent of CAL from PhotoClick liposomes in Xray. Comparatively, liposomes lacking PhotoClick components showed negligible
release over the time span measurements were taken. 100% release was achieved by
treating Photoclick liposomes with Triton X-100.
DOX Release from PhotoClick Liposomes After X-ray Exposure
Next, we focused on investigating the release of DOX from PhotoClick
liposomes. 400 nm Stealth liposomes were prepared by extrusion in an acidic
environment based on the citrate buffer. The first buffer exchange with a neutral buffer
(pH 7.2) was performed by overnight cassette dialysis. Liposomes were actively loaded
with DOX by adding the drug to the bulk solution at 125 µM final concentration after the
buffer exchange. The active loading procedure lasted for four days, after which the nonincorporated DOX was removed by overnight cassette dialysis against 2 L of drug-free
buffer (pH 7.2).
The experiment for X-ray controlled drug release comprised exposure to radiation
of 100 µL PhotoClick liposomes in 1.2 mL buffer (Y in Figure 29). The 100% release
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efficacy was determined from PhotoClick liposomes treated with 100 µL of 5% v/v
Triton X-100 (Z in Figure 29). A background control consisted of PhotoClick liposomes
not exposed to ionizing radiation (X in Figure 29). The fluorescence of DOX released
from liposomes was determined for all samples and controls approximately six minutes
after completing the irradiation. The control background sample (PhotoClick liposomes,
no exposure) did not show any substantial release of DOX at rest. In contrast, the
exposed PhotoClick liposomes showed a sustained leakage, as indicated by the large
fluorescence signal recorded after exposure. Compared with the 100% release efficacy
realized by Triton X-100 treatment of the liposomes, around 50 % of the incorporated
DOX was released from the PhotoClick liposomes in less than 10 minutes (Figure 29).
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Figure 14.
X-ray induced release of DOX from PhotoClick liposomes. Relative
release percent intensity of non-irradiated PhotoClick liposomes loaded with DOX
(X), irradiated PhotoClick liposomes loaded with DOX (Y), and PhotoClick
liposomes loaded with DOX and treated with Triton X-100 (Z) (100% release). p <
0.01 between Y and X (n = 3).
CIS Release Upon X-ray Exposure
Another frequently used anticancer drug, CIS, was also investigated by using the
PhotoClick liposomes. Since CIS does not present fluorescent properties, analysis of CIS
release comprised absorbance measurements [59-61]. Prior to analysis of release, a
standard curve was created to determine the absorbance behavior of CIS in relation to
concentration (Figure 30). The CIS standard curve shows that CIS concentration may be
accurately determined with a spectrometer, although it was not utilized to quantify the
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release efficacy in an absolute manner since the total inner volume of the liposomes in
the samples is not known.

Figure 15.

A standard curve for CIS is established by measuring the absorbance
of the colorimetric product at 704 nm (n = 3).

After the concentration standard curve for CIS was established, an analysis was
made regarding the relative release of CIS from PhotoClick liposomes. The comparison
was done relative to the absorption data with the maximum release (100%) achieved
upon treatment with 50 µL of 5% v/v Triton X-100 of the same PhotoClick liposomes.
All samples were prepared by mixing 100 µL of dialysis-purified liposomes loaded with
0.1 mg/mL CIS with 0.9 mL buffered electrolyte (135 mM KCl, 20 mM HEPES, pH 7.2).
A non-PhotoClick control and PhotoClick liposomes were irradiated with .125 MeV Xray. As an additional control, a sample of PhotoClick liposomes was also rested. 140
minutes after treatment, all the liposome mixtures were centrifuged at 4 °C and 20,000
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RPM (Labnet Hermle zk36, rotor #19), filtered through 22 nm Whatman filters, and the
filtrate was incubated in OPDA/ DMF in sealed vials as described in the Materials and
Methods section. After allowing contents to cool to room temperature, absorbance was
measured, and the relative release efficacy estimated (Figure 31).

Figure 16.
CIS release upon X-ray exposure of PhotoClick liposomes. PhotoClick
liposomes loaded with CIS at rest (A), irradiated control liposomes loaded with CIS
(B), irradiated PhotoClick liposomes loaded with CIS (C), and PhotoClick liposomes
loaded with CIS and treated with Triton X-100 (D) (100% release). p < 0.01 between
C and A as well as C and B (n = 3).
As Figure 31 shows, both controls indicate negligible CIS release; this is
indicative of the requirement of X-ray for PhotoClick liposomes to present an increased
membrane permeability, as well as stability of non-irradiated PhotoClick liposomes.
Within the indicated time frame, approximately 60% of the incorporated CIS was
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released from PhotoClick liposomes following irradiation (C) as compared to the same
composition liposomes released by Triton X-100 (D). The non-irradiated PhotoClick
liposomes (A) showed a great stability, and negligible amounts of the incorporated drug
was released at rest. The irradiated control liposomes (containing no PhotoClick
components, B) also showed satisfactory stability upon irradiation, with negligible
amounts of the drug released within the same time frame, yet slightly more than the
rested PhotoClick liposomes. A reasonable explanation of this slightly reduced stability
may be provided by considering oxidation and radiolysis processes induced by the
exposure to ionizing radiation of this particular composition.
Controlled Release From pH-Sensitive Liposomes
pH-sensitive liposomes have long been envisioned as appropriate carriers for
delivery of cargo under controlled conditions [19, 38, 71]. As the name suggests, pHsensitive liposomes undergo modulation of their membrane’s permeability as a function
of pH. Such changes are readily achievable in vitro, when pH adjustment may be
produced by simple addition of proton donors or acceptors to the bulk; in this case, the
only stringent requirement is for the target pH not to diminish the chemical reactivity or
biological activity of the cargo molecules. However, for the purpose of drug delivery pH
modulation in vivo is not an easy task. Since their inception, pH-sensitive liposomes have
been considered ideal vehicles for cancer therapy since evidence points towards an acidic
pH in the tumor microenvironment. Unfortunately, this varies between large values, it is
not predictable, and many times the acidification is very small [72, 73]. Nonetheless,
organic halogens provide the opportunity to locally control the pH by utilizing the
sustained proton release upon exposure to ionizing irradiation [48, 50, 51]. We exploited
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this feature and produced pH-sensitive liposomes, which were further exposed to ionizing
radiation (X-ray) to initiate drug delivery.
Based on one of the many recipes presented in literature [38], we produced 400
nm pH-sensitive liposomes composed of DSPC, PE, Chol, OA, and DSPE-PEG at mass
ratios of 10:3.3:1.2:0.7:2.1. The liposome sample intended for exposure to X-ray was
hydrated with 150 mM bromal hydrate (brought to pH 7.2 with NaOH) and 3 mM CAL.
A different compositional mixture, non-pH-sensitive (DSPC: Chol: DSPE-PEG, mass
ratio of 10:1.2:2.1) hydrated with 135 mM KCl (pH 7.2) and 3 mM CAL was used as an
X-ray exposed control. An additional test sample utilized for testing the drug release
upon external exposure to an acidic pH had identical pH-sensitive composition but was
hydrated with 135 mM KCl (pH 7.2) and 3 mM CAL. Upon production, all liposome
samples were purified by cassette dialysis.
The first test involved investigating the release of dye from the pH sensitive test
liposomes upon acidification of the external bulk by HCl addition. When the external pH
was changed from 7.2 to 6.44, a sudden increase in the fluorescence signal of CAL was
recorded (Figure 32), indicative of CAL leakage from the pH sensitive liposomes. The
release of the dye was relatively slow, which is characteristic to pH-sensitive liposomes.
Nonetheless, external change of the pH led to the release of approximately 75% of the
incorporated dye (based on comparison with Triton X-100 induced release) in less than
one hour.
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Figure 17.
CAL release from pH sensitive liposomes. External pH was reduced
from 7.2 to 6.44 by addition of dilute HCL. Percent release is normalized to an
identical liposome sample treated with Triton X-100
Once our investigations indicated that the dye may be released upon acidification.
We exposed the pH-sensitive liposomes filled with BH to X-ray (0.125 MeV); the control
(not pH-sensitive) was simultaneously exposed to identical conditions. Another sample
with PhotoClick liposomes, not exposed to X-ray, was utilized as leakage indicator at
rest; the fluorescence spectra of all samples were recorded after four hours (Figure 33). A
non-exposed sample presented a high fluorescent signal after membrane solubilization
with 50 µL of 5% v/v Triton X-100 (#4, 100% release efficacy); an identical non-exposed
sample showed negligible fluorescence in the absence of membrane solubilization (#1).
The non-pH sensitive liposomes also showed negligible release upon exposure to X-ray
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(#2). However, the pH-sensitive liposomes exposed to X- ray showed over 50% release,
indicative of sustained dye leakage (#3).
The only reasonable explanation for the increased release upon X-ray exposure is
that irradiation of the BH solution led to a massive release of protons [48-56]. which
acidified the intraliposomal space. Upon acidification, the membrane composed of pHsensitive lipids underwent an increase in permeability; this leakage reduced the dye
concentration, which led to the observed increase in fluorescence.

Figure 33.
Relative release of CAL fluorescence intensity of pH sensitive CAL
and BH loaded liposomes. pH sensitive liposomes at rest (1), non-pH sensitive
control liposomes loaded with CAL and irradiated with X-ray (2), pH sensitive CAL
and BH loaded liposomes irradiated with X-ray (3), pH sensitive CAL and BH
loaded liposomes treated with Triton X-100 (4). p < 0.01 between 3 and 1 as well as 3
and 2 (n = 3).
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Conclusions
Our investigations led to the conclusion that liposomes may be tailored to release
their payload in a controllable fashion and by using ionizing radiation as a triggering
mechanism. The two modalities of controlled drug release presented here rely on direct
and indirect adjustments of the membrane permeability upon X-ray exposure. For the
PhotoClick liposomes, specific components in the membrane undergo covalent bonding,
which translates into reduced fluidity and increased permeability. The intimate
mechanisms by which such changes occur under exposure to ionizing radiation are still
obscure. PhotoClick components are designed to interact directly with UV photons [23,
74] which have a much lower energy than X-ray. Likewise, it has been documented that
photopolymerizable lipids also interact with UV light when included into liposome
membranes, rendering the vesicular structures responsive to X-ray [30]. However, it is
not clear if initiation of polymerization is a consequence of direct interaction with high
energy photons or through indirect radiolysis products. Nonetheless, an important
conclusion from this prior work relates to the important role presented by lipid separation
into domains. Our work exploits this important feature by including components known
to segregate into lipid rafts (i.e., SM, and Chol [25, 67]), which apparently promote
covalent bonding between neighboring molecules without the need of other
transmembrane components. The investigations do not provide any indication if the cargo
is either released through the segregated domain or around it; such investigations may be
initiated by determining the permeability changes in response to radiation by adjusting
the size of the lipid rafts to maximize either their surface area or perimeter while
maintaining a satisfactory stability of the liposomes at rest.
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As an alternative to PhotoClick liposomes, cargo release from pH sensitive
liposomes is well documented in literature, and many compositions responsive to pH
changes for a relatively large range of pHs have been reported [47]. However, our
investigations focused on controlling the release by adjusting the internal pH via proton
release from organic halogen solutions exposed to ionizing radiation [48-56], which
provides opportunities for real control over release upon external stimulation. This is not
a common feature of other release mechanisms, which rather rely on potential
physiological pH variations at the site to achieve drug delivery [18, 71].
Both approaches presented here show that drug release can be initiated by
utilizing liposomes specially designed to respond to X-ray and adjust the membrane
permeability through direct and indirect interactions with the ionizing radiation.
However, technical limitations restricted our investigations to only relatively low X-ray
energies. While this may be an option for controlled drug delivery without added
radiotoxicity, modern tumor treatment by radiotherapy usually employs much larger
energies. We anticipate that a larger energy would accelerate the release of drugs from
pH sensitive liposomes filled with organic halogens since the pH changes monotonically
follow the energy and dose in the MeV range [53, 56]. Nonetheless, we do not know the
behavior of PhotoClick components at large energies. If the covalent bonding is an
indirect effect of radiolysis products, we anticipate that higher energies leading to a more
sustained radiolysis will accelerate the release rate. However, if the direct hit is chiefly
responsible for initiating covalent bonding, insufficient stopping power may prevent
covalent bonding and effective membrane permeabilization at high energies; this could
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be prevented by radiation fractionation in terms of both energy and dose during
treatment.
Finally, we showed that X-ray radiation may be used to trigger drug release from
specially designed liposomes by changes in the membrane permeability induced by two
different mechanisms. Such approaches pave the way for achieving simultaneous and
highly localized chemo and radiotherapy, which is postulated to significantly improve the
clinical outcome of cancer therapy by reducing the systemic effects of classical
chemotherapy, enabling achievement of higher drug concentrations only at the diseased
site, and benefiting from the supra-additive effects of the combined therapy approach.
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CHAPTER FIVE: CONCLUSIONS AND PERSPECTIVES
Through the span of the previous chapters, we caught a small glimpse of the vast
and intricate world of liposomes. The long-revered concept of spherical bilayers made of
phospholipids is relatively simple and straightforward. They found applicability in
science, biotechnology, medicine, and other fields. Continuous advancements and
progress have been the result of the investigations scientists have made looking into
developing novel means for their production, as well as finding scientific or medical
applications difficult to achieve by utilizing alternative approaches and practices. In this
respect, the focus of this dissertation pertains to better understanding their production and
providing potential improvements for their application as drug carriers.
Having been a keen topic of research since their discovery in the 60’s, initial
interest chiefly resided in their formation and production [1]. The realization that they
could be used as drug carriers in the following decades only increased interest in them,
ranging from their production, to formation, to composition. The basic requirements for
drug carriers include retaining and protecting the drugs, evading the immune system of
the host, targeting the desired organ or tissue, and releasing the drug in a controlled
manner. Liposomes satisfy many of these needs [2, 3]. The protective membrane encases
a water-filled cavity that can be passively or actively loaded with hydrophilic drugs and
molecules of interest. In addition, hydrophobic drugs and molecules may be included in
the hydrophobic core of the phospholipid membrane, therefore liposomes present a great
versatility with respect to their ability to retain and protect various cargos of interest, as
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well as transporting them to a desired location within the host. The ability to
functionalize their surface by bioconjugation endows liposomes with endless targeting
capabilities, which is essential for avoiding a systemic release of the bioactive cargo. This
feature is crucial for the release of antineoplastic drugs used for the treatment of solid
tumors. In the case of small liposomes (diameters below 200 nm), they self-accumulate
into tumors via the EPR effect [4-6]. The added ability to avoid immune detection by
PEGylation made liposomes particularly appealing for use as chemotherapeutic carriers
[7]. These attributes are essential in making them available on the pharmaceutical market
and as an FDA approved treatment option for cancer [8]. Although triggered release
methods for liposomal content are being considered and undergoing greater exploration
to enhance their usefulness, use in a clinical setting is still in the early stages of clinical
research and years from final approval.
Our initial explorations investigated liposome production by hydration,
sonication, and extrusion. Early assessment investigated size and distribution using DLS
and microscopy, with comparison between liposomes of regular (asolectin and
cholesterol) and PEGylated (DSPC, DSPE-PEG, and cholesterol) membrane
composition. Furthermore, liposomes were prepared and loaded using both passive and
active methods. Finally, we established that containment and release of both actively and
passively loaded liposomes could be monitored with the use of fluorescent molecules
such as CAL, R6G, AO, and DOX. This relied on the fluorescence self-quenching
properties of all the molecules used, allowing us to confirm high loading concentrations
by inducing release using a non-ionic detergent to solubilize the liposomal membranes,
resulting in a significant fluorescence increase resulting from cargo dilution into the bulk.
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Next, we delved into the exploration of new methods for the production and
purification of liposomes. Traditional approaches require multiple steps which require
lengthy periods of waiting, resulting in a lag between initial demand and availability.
Knowing that detergent removal is a proven method of liposome formation, we exploited
this feature and significantly sped up the process by utilizing ionic detergents which we
later removed by using an electrophoretic force. The electrodialysis-driven depletion
(EDD) method not only enabled simultaneous production, loading, and purification of,
but was also applicable to obtaining long-circulating liposomes. The potential of this
technique was further proven by showing comparable size and distribution characteristics
of EDD-produced liposomes to those made by extrusion and sonication. Although the
procedure is limited to effectively purifying only charged molecules, it allows the rapid
production of loaded and purified liposomes from lipid film in a matter of hours from
start to finish. With classic approaches, the entire process can take multiple days. In many
instances, EDD could allow for same day preparation and experimentation with
liposomes, possibly extending into medical applications. The extraordinary potential of
this technique must be further investigated to understand the full scope of its capabilities
and possibility for modification [9].
As stated earlier, one of the major standing challenges for drug delivery via
liposomes is the release of the cargo in a well-controlled manner. In this respect, we
proposed and investigated two novel controlled release methods to deliver liposomal
contents at will. The first approach exploits the crosslinking properties of photosensitive
PhotoClick components upon UV exposure. Not only were we able to confirm membrane
permeabilization in liposomes with PhotoClick components under UV irradiation, but we
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also showed that PhotoClick component bearing liposomes are similarly responsive to Xray. In addition, we utilized known increase of membrane permeability of pH sensitive
liposomes in combination with loaded radiation-sensitive bromal hydrate (BH) to achieve
controlled release. Upon X-ray exposure, the loaded BH decomposed and induced a pH
drop, causing permeabilization of pH sensitive membranes and leading to cargo release.
The importance of these studies does not only reside in demonstration of the highly
localized and controlled capabilities of X-ray driven cargo release from specially
formulated liposomes, but also the potential of X-ray to be used as a concomitant
treatment with release of chemotherapeutic. The reduced combined toxicity of
simultaneous radiation and chemotherapy application made possible by such liposomes
could dramatically improve clinical outcomes of cancers treated in this manner due to the
suggested synergistic benefits of concomitant radio-chemotherapy treatment [10, 11].
Beyond increasing the effectiveness of treatment, this combination could also allow for
overall smaller doses of both chemotherapy and radiation [12].
Outlooks and Perspectives
There is no doubt that the biomedical applications of liposomes will undergo a
continuous expansion in the coming years. Promising results have been already achieved
for incorporating into liposomes various anticancer drugs such as cisplatin, paclitaxel,
and temozolomide, [13-15], which will enable direct clinical applications to cancer for
which systemic chemotherapy is currently the only option. Immunotherapy is one of the
newest advances in cancer treatment, and we are confident that liposomes will be soon
utilized to improve the clinical outcome of such therapies. The ability to use radiation for
simultaneous radiotherapy and localized chemotherapy is anticipated to significantly
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improve the local and loco-regional control of tumors. Another expected advancement is
providing liposomes with targeting and killing capabilities of circulating cancer cells,
with direct clinical applicability to metastasis control and treatment [16].
Biomedical applications for liposomes are also not limited as drug carriers. Their
versatility has been shown as having potential applications as both therapeutic and
diagnostic tools (theranostics) [17]. Furthermore, liposomes have been proposed as
antivirulence factors, serving to compete with host cell membranes to absorb toxins. This
has been shown to significantly inhibit the lytic activity of toxins [18], which suggests
possible use of specially formulated liposomes to mitigate biological activities of
virulence factors and contribute to improving the treatment of infectious diseases.
The ever-developing world of liposomal research shall continue to impress us
with newer and better applications. Simple, yet versatile, liposomes will further prove
their worth and capabilities with the progression of time. Whether it is for medical
treatments, diagnostics, fundamental research of membranes, food sciences, or even
agriculture, they enhance the capabilities of much that was previously considered
impossible, unlikely, and impractical.
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